

Augmentation

Breast Augmentation with *NATRELLE*[®] Silicone-Filled Breast Implants and *NATRELLE INSPIRA*[®] Breast Implants

Smooth surface implants

WARNING:

- Breast implants are not considered lifetime devices. The longer people have them, the greater the chances are that they will develop complications, some of which will require more surgery.
- Breast implants have been associated with the development of a cancer of the immune system called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). This cancer occurs more commonly in patients with textured breast implants than smooth implants, although rates are not well defined. Some patients have died from BIA-ALCL.
- Patients receiving breast implants have reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.

The sale and distribution of this device is restricted to users and/or facilities that provide information to patients about the risks and benefits of this device in the form and manner specified in the approved labeling provided by Allergan.

TABLE OF CONTENTS

BOXED WARNING	COVER PAGE
GLOSSARY	3
1.0 CONSIDERING SILICONE GEL-FILLED BREAST IMPLANT SURGERY	11
1.1 What Gives the Breast Its Shape?	12
1.2 What Is a Silicone-Filled Breast Implant?	12
1.3 Who is eligible for NATRELLE® Silicone-Filled Breast Implants and NATRELLE INSPIRA® Breast Implants?	17
1.4 Who Should not get Breast Implants (What are the Contraindications)?	17
1.5 Precautions	18
1.6 Warnings	18
2.0 BREAST IMPLANT BENEFITS AND RISKS	19
2.1 What Are the Benefits?	20
2.2 What Are the Potential Risks?	20
2.3 What Causes Breast Implants to Rupture and How Can I Tell if My Implants Are Ruptured?	29
2.4 What Are Other Reported Conditions?	31
3.0 SURGICAL CONSIDERATIONS FOR BREAST AUGMENTATION	35
3.1 What are the Alternatives to Breast Augmentation with NATRELLE® Silicone-Filled Breast Implants or NATRELLE INSPIRA® Breast Implants?	35
3.2 What Are Questions to Consider When Choosing a Surgeon?	35
3.3 What Are Choices and Options Associated with the Surgery?	37
4.0 FOLLOW-UP EXAMINATIONS	43
5.0 ALLERGAN'S CLINICAL STUDY RESULTS	44
5.1 What Are the Overview Findings of Allergan's Core Study?	45
5.2 What Are the 10-Year Follow-Up Rates?	45
5.3 What Are the Benefits?	46
5.4 What Are the 10-Year Complication Rates?	48
5.5 What Are the Main Reasons for Reoperation?	50
5.6 What Are the Main Reasons for Implant Removal?	53
5.7 What Are Other Clinical Data Findings?	54

<u>6.0</u> <u>ADDITIONAL INFORMATION</u>	56
6.1 <u>What If I Experience a Problem?</u>	56
<u>Device Identification Card</u>	56
6.2 <u>What Is Device Tracking?</u>	56
6.3 <u>What Is the <i>ConfidencePlus</i>[®] Limited Warranty?</u>	57
6.4 <u>How Can I Receive More Information?</u>	58
6.5 <u>What is the National Breast Implant Registry?</u>	59
<u>FOR FURTHER READING AND INFORMATION</u>	60
<u>INDEX</u>	67
<u>ACKNOWLEDGEMENT OF INFORMED DECISION AND PATIENT DECISION CHECKLIST</u>	69
<u>PATIENT DECISION CHECKLIST</u>	69

GLOSSARY

Areola	The pigmented or darker colored area of skin surrounding the nipple of the breast.
Asymmetry	Uneven appearance between a woman's left and right breasts in terms of size, shape, or breast level.
Atrophy	Thinning or diminishing of tissues or muscle.
Autoimmune disease	An autoimmune disease is a disease in which the body's immune system attacks its own cells or tissues by mistake, causing damage and dysfunction. Autoimmune diseases can affect connective tissue in the body (the tissue that binds together body tissues and organs). Autoimmune diseases can affect many parts of the body, like nerves, muscles, glands, and the digestive system.
Axilla	The junction of your arm and your body (armpit).
Biocompatible	The ability to exist along with living tissues or systems without causing harm.
Biopsy	The removal and examination of tissues, cells, or fluid from the body.
Body Dysmorphic Disorder	A psychological condition characterized by excessive worry about an imagined or minor physical flaw to the point that it can interfere with normal daily activities.
Body Esteem Scale	A questionnaire which asks about a person's body image.
Breast augmentation	A surgical procedure to increase breast size. For this document, it refers to placement of a breast implant. The first time a breast implant is placed for augmentation is called "primary augmentation." Any time there is another surgery to replace the implant, it is referred to as "revision-augmentation."
Breast implant	Any surgically implanted artificial device intended to replace missing breast tissue or to enhance a breast.
Breast Implant Associated Anaplastic large cell lymphoma (BIA-ALCL)	BIA-ALCL is not breast cancer; it is a rare type of non-Hodgkin's lymphoma, a cancer involving the cells of the immune system.
Breast mass	A lump in the breast.

Breast reconstruction

A surgical procedure to replace breast tissue or reconstruct a breast after tissue was taken out because of cancer or injury. Breast reconstruction also includes the surgical correction of a breast that has failed to develop properly due to a severe abnormality or congenital defect. For this document, it refers to placement of a breast implant.

Calcification

Process of hardening by calcium salts.

Capsular contracture

A tightening of the scar tissue (also called a capsule) that normally forms around the breast implant during the healing process after surgery. In some women, the scar tissue (capsule) squeezes the implant. When this occurs, it is called capsular contracture. This results in firmness or hardening of the breast and is a risk for implant rupture. Capsular contracture is classified by Baker Grades. Capsular Contracture Baker Grades III or IV are the most severe. Baker Grade III often results in the need for additional surgery (reoperation) because of pain and possibly abnormal appearance. Baker Grade IV usually results in the need for additional surgery (reoperation) because of pain and unacceptable appearance. Capsular contracture Baker Grade II may also result in the need for surgery. Each grade is described below.¹¹

- Baker Grade I – Normally soft and natural appearance
- Baker Grade II – A little firm, but breast looks normal
- Baker Grade III – More firm than normal, and looks abnormal (change in shape)
- Baker Grade IV – Hard, obvious distortion, and tenderness with pain

Capsule

Scar tissue which forms around the breast implant.

Capsulotomy (closed)

An attempt to break the scar tissue capsule around the implant by pressing or pushing on the outside of the breast. This method does not require surgery but may rupture the implant and is contraindicated.

Capsulotomy (open)	An attempt to break the scar tissue capsule around the implant by surgical incision into the capsule.
cc	Cubic centimeters. A measure of implant volume. The higher the cc value, the higher the implant volume. For example, an 800 cc implant is larger than a 200 cc implant.
Congenital abnormality	An abnormal development in part of the body, present in some form since birth.
Connective tissue disease/disorder (CTD)	A disease, group of diseases, or conditions affecting connective tissue, such as muscles, ligaments, skin, etc., and/or the immune system. Connective tissue diseases (CTDs) that involve the immune system include autoimmune diseases such as rheumatoid arthritis, lupus, and scleroderma.
Contraindication	A use that is improper and should not be followed. Failure to follow contraindications identified in the labeling could cause serious harm.
Contralateral	Opposite side.
Core Study	The primary clinical study of augmentation, reconstruction, and revision (revision-augmentation and revision-reconstruction) patients that supported the approval of the premarket approval (PMA) application. Safety and effectiveness data are collected yearly through 10 years, with the follow-up from years 5 through 10 being performed as part of a post-approval Core Study.
Delayed wound healing	Unusually slow progress in the healing of a wound; surgical incision site fails to heal normally or takes longer to heal.
Displacement	Movement of the implant from the usual or proper place.
Extrusion	Skin breakdown with the implant pressing through the skin or surgical incision.
Fibromyalgia	A disorder characterized by chronic pain in the muscles and soft tissues surrounding joints, with tenderness at specific sites in the body. It is often accompanied by fatigue.
Fibrous tissues	Connective tissues composed mostly of fibers.
Gel bleed	When silicone gel leaks or “bleeds” or diffuses through the implant shell.

Gel fracture	Appearance of a fissure or fault line in highly cohesive gel in response to an applied force.
Granuloma	A noncancerous lump that can form around any foreign material, such as silicone. Like any lump, it should be evaluated to distinguish it from a lump that might be cancerous.
Hematoma	A collection of blood within a space.
Hypertrophic scarring	An enlarged scar remaining after a wound heals.
Incision	A cut made to the tissue during surgery.
Infection	The growth in the human body of microorganisms such as bacteria, viruses, or fungi. An infection usually results in fever, swelling, redness, and/or pain. It can occur as a result of any surgery.
Inflammation	The response of the body to infection or injury that is characterized by redness, swelling, warmth, and/or pain.
Inframammary	Below the breast.
Inpatient surgery	A surgical procedure in which the patient is required to stay overnight in the hospital.
Lactation	The production and secretion of milk by the breast glands.
Low molecular weight silicones	Small silicone molecules that might leak out of the implant.
Lymph nodes	Glands that play an important part in the body's defense against infection. They produce lymph, which travels throughout the body in the lymph system, and filters impurities from the body. Common areas where the lymph nodes can be felt with the fingers include: groin, armpit, neck, under the jaw and chin, behind the ears, and on the back of the head.
Lymphadenopathy	Enlargement of the lymph node(s).
Lymphedema	Swelling of the lymph node(s).
Malposition	When the implant is placed incorrectly during the initial surgery or when the implant has shifted from its original position. Shifting can be caused by many factors, such as gravity, trauma, poor initial placement, and capsular contracture.

Mammary	Pertaining to the breast.
Mammography	A type of X-ray examination of the breasts used for detection of cancer. Screening mammography – x-ray examination of the breast that is performed on women with no complaints or symptoms of breast cancer; the goal is to detect breast cancer when it is still too small to be felt by a physician or the patient. Diagnostic mammography – x-ray examination in order to evaluate a breast complaint or abnormality detected by physical exam or screening mammography; additional views of the breast are usually taken.
Mammoplasty	Plastic surgery of the breast.
Mastitis	Inflammation of the breast.
Mastopexy	Surgical procedure to raise and reshape sagging breasts.
Metastatic disease	A stage of cancer after it has spread from its original site to other parts of the body.
Migration	Movement of silicone materials outside the breast implant to other parts of the body.
MRI (Magnetic Resonance Imaging)	A radiographic examination that currently has the best ability to detect rupture of silicone gel-filled breast implants.
Necrosis	Death of cells or tissues.
Outpatient surgery	A surgical procedure in which the patient is not required to stay in the hospital overnight.
Palpability	The ability to feel the implant.
Palpable	Felt with the hand.
Patch assembly	The patch assembly seals the implant shell.
Pectoralis	Major muscle of the chest.
Periareolar	Around the darkened or pigmented area surrounding the nipple of the breast.
Plastic surgery	Surgery intended to enhance or improve the appearance of the body.
Pneumothorax	Pneumothorax (sometimes called "collapsed lung") occurs when air leaks into the space between the lung and chest wall.
Postoperative	After surgery.

Precautions	Information that warns the reader of a potentially hazardous situation which, if not avoided, may result in minor or moderate injury.
Primary breast augmentation	The first time a breast implant is placed for the purpose of breast augmentation.
Ptosis	Sagging or drooping of the breast.
Reoperation	An additional surgery after your first breast implantation.
Revision-augmentation	Refers to the correction or improvement of a primary augmentation. For this document, it refers to surgical removal and replacement of breast implants that were placed originally for primary breast augmentation.
Revision-reconstruction	Refers to the correction or improvement of a primary reconstruction. For this document, it refers to surgical removal and replacement of breast implants that were placed originally for primary breast reconstruction.
Rheumatologic disease/disorder	A variety of diseases involving connective tissue structures of the body, especially the joints and fibrous tissue. These diseases are often associated with pain, inflammation, stiffness, and/or limitation of motion of the affected parts. Can include autoimmune diseases. Fibromyalgia is a rheumatological disorder.
Rosenberg Self-Esteem Scale	A questionnaire that measures overall self-esteem.
Rowland Expectation Scale	A 16 item questionnaire intended to measure expectations and perceived results of implant surgery.
Rupture	A tear or hole in the shell of the implant that allows silicone gel filler material to leak from the shell. Ruptures can be intracapsular (inside the scar tissue capsule surrounding the implant) or extracapsular (outside the scar tissue surrounding the implant).
Saline	A solution made of water and a small amount of salt.
Scar revision	A surgical procedure to improve the appearance of a scar.

Seroma	Similar to a bruise, a seroma occurs when the watery portion of the blood collects around a surgical incision or around a breast implant.
SF-36 Scale	The Short Form 36 Health Scale; a questionnaire intended to measure physical, mental, and social health.
Silent rupture	A breast implant rupture without symptoms or a visible change. Silent rupture cannot be felt by the woman or detected by a doctor through physical examination. Silent rupture can only be discovered through appropriate imaging techniques such as MRI. Most silicone gel-filled breast implant ruptures are silent (see symptomatic rupture below).
Silicone elastomer	A type of silicone that has elastic properties similar to rubber.
Subglandular placement	Placement of a breast implant underneath and within the breast glands but on top of the chest muscle.
Submuscular placement	Placement of a breast implant wholly or partially underneath the chest muscle.
Symptom	Any perceptible change in the body or its functions that indicates disease or a phase of a disease.
Symptomatic	Experiencing symptoms; any evidence or sign of disease or disorder.
Symptomatic rupture	A breast implant rupture that is associated with symptoms (such as lumps, persistent pain, swelling, hardening, or change in implant shape). Some silicone breast implant ruptures are symptomatic, but most are silent.
Systemic	Pertaining to or affecting the body as a whole.
Tennessee Self-Concept Scale	A questionnaire intended to measure the patient's view of her body and state of health, as well as her attitude about appearance, skills, and sexuality. The questionnaire administered in the Core Study consisted of 18 items.

Toxic shock syndrome

A rare, but life-threatening bacterial infection that may occur after surgery. It occurs most often in the vagina of menstruating women using superabsorbent tampons. Symptoms include sudden high fever, vomiting, diarrhea, decreased blood pressure, fainting, dizziness, and sunburn-like rash. A doctor should be seen immediately for diagnosis and treatment if toxic shock syndrome is suspected.

Transaxillary Warning

Under the arm.

Statement that alerts the reader about a situation which, if not avoided, could result in serious injury or death.

1.0 CONSIDERING SILICONE GEL-FILLED BREAST IMPLANT SURGERY

You may be considering breast implant surgery to increase the size of your breasts. This is referred to as breast augmentation. Or you may need to have a previous breast augmentation corrected or improved, which is called revision-augmentation. Allergan has prepared this information to help you better understand the breast implant procedure and assist you in making an informed decision about breast augmentation or revision-augmentation surgery. It will help to answer some of the questions you may have about the surgery and about breast implants in general. It will also provide you with specific information about the risks and benefits of Allergan's **NATRELLE**[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®] Breast Implants. Similar information to help you understand breast reconstruction is available from your plastic surgeon, Allergan, or at www.allerganlabeling.com.


This information cannot and should not replace talking with your plastic surgeon. Your decision whether or not to get breast implants should be based on realistic expectations of the outcome. There is no guarantee that your results will match those of other women. Your results will depend on many individual factors, such as your overall health (including age), chest structure, breast/nipple shape and position, skin texture, healing capabilities (which may be slowed by radiation and chemotherapy treatment, smoking, alcohol, and various medications), tendency to bleed, prior breast surgery, surgical team's skill and experience, type of surgical procedure, and type and size of implant. Make sure you speak with your surgeon about your expectations of the results, as well as what you can expect regarding the length of the surgery, your recovery, and any risks and potential complications of the surgery. Ask questions.

As part of your decision, both you and your surgeon should sign Allergan's "[Acknowledgement of Informed Decision and Patient Decision Checklist](#)" form that confirms your understanding of the risks and benefits of Allergan's **NATRELLE**[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®] Breast Implants. This form is located at the end of this document.

Because breast implants will require monitoring and care for the rest of your life, you should wait at least 1-2 weeks after reviewing and considering this information before deciding whether to have primary breast augmentation surgery. In the case of a revision-augmentation, however, your surgeon may find it medically advisable to perform your surgery sooner.

1.1 What Gives the Breast Its Shape?

The breast consists of milk ducts and glands, surrounded by fatty tissue that provides its shape and feel. Beneath the breast is the chest muscle (pectoralis major muscle).



Implants are used to make the breast larger or to restore/replace breast tissue. Factors such as pregnancy (when milk glands are temporarily enlarged), rapid weight loss, and the effects of gravity as you age combine to stretch the skin, which may cause the breast to droop or sag. However, it is important to realize that implants are used to make the breast larger. The implants alone may not adequately lift the breast, or correct the effects of pregnancy, weight loss, or skin stretching. Your surgeon may suggest additional procedures at the time of the breast augmentation, such as mastopexy, to help achieve improved breast lift.

1.2 What Is a Silicone-Filled Breast Implant?

A silicone gel-filled breast implant is a sac (implant shell) of silicone elastomer (rubber) filled with silicone gel. Allergan has approval for three types of silicone gel fillers: *Responsive* silicone gel, *SoftTouch* silicone gel, and *Highly Cohesive* silicone gel. Each gel filling varies in the amount of firmness it provides to the implant. Responsive silicone gel is the least firm gel and Highly Cohesive is the most firm gel offered. SoftTouch silicone gel has a firmness level that is in between that of the Responsive silicone gel and the Highly Cohesive silicone gel. This document focuses on round implants filled with each of the three gel types.

Allergan offers two lines of round silicone-filled breast implants: **NATRELLE®** Silicone-Filled Breast Implants and **NATRELLE INSPIRA®** Breast Implants. **NATRELLE®** Silicone-Filled Breast Implants are filled with *Responsive* silicone gel. **NATRELLE INSPIRA®** Breast Implants are

filled with *Responsive* silicone gel (**NATRELLE INSPIRA**[®] *Responsive* Breast Implants), *SoftTouch* silicone gel (**NATRELLE INSPIRA**[®] *SoftTouch* Breast Implants), and *Highly Cohesive* silicone gel (**NATRELLE INSPIRA**[®] *Cohesive* Breast Implants).

Product Name	Gel Filling
NATRELLE [®] Silicone-Filled Breast Implants	Responsive silicone
NATRELLE INSPIRA [®] Responsive Breast Implants	Responsive silicone
NATRELLE INSPIRA [®] SoftTouch Breast Implants	SoftTouch silicone
NATRELLE INSPIRA [®] Cohesive Breast Implants	Highly Cohesive silicone

NATRELLE[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®] Breast Implants come in a variety of profiles and sizes. The images shown below are examples of the **NATRELLE**[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®] Breast Implants you may have seen at your surgeon’s office. A number of factors will determine which style and size of breast implant is most appropriate. These factors include your breast augmentation goals, your body size, your desired breast size, and the amount of breast skin you have. Your plastic surgeon will discuss with you the implant options that will best help you achieve the result that is right for you. [Refer to Section 3.3](#) for more information on the different **NATRELLE**[®] Silicone-Filled Breast Implants and lines of **NATRELLE INSPIRA**[®] Breast Implants available from Allergan.

Example of a **NATRELLE**[®] Silicone-Filled Breast Implant



Example of **NATRELLE INSPIRA**[®] Smooth Breast Implant



NATRELLE® Silicone-Filled Breast Implant Device Materials

The potential toxicity of the chemicals and metals listed in the following tables have been evaluated with both toxicity testing and risk assessments to assess the exposure levels in comparison to the amount determined to likely be safe. All detected elements were below levels that are considered unsafe. However, individual responses to chemicals may vary, and all reactions cannot be predicted. Most of these chemicals stay inside the shell of the implant but small quantities have been found to diffuse (gel bleed) through the implant shell of silicone gel-filled implants, even if the implant is intact and not ruptured or leaking.

Breast Implant Device Materials

Implant Component	Device Materials
Shell, inner/outer layers	Dimethyl Silicone Elastomer Dispersion
Shell, barrier layer	Diphenyl Silicone Elastomer Dispersion
Shell textured layer	MED-6400 Silicone Elastomer
Patch assembly	MED 2174 and MED 2-6650 Silicone Elastomer
Gel	Silicone Gel: Base and Crosslinker; platinum cure

Chemicals Released by NATRELLE® Silicone-Filled Breast Implants

Volatiles: Chemicals that are released by breast implants as a gas.

Extractables: Chemicals that are released by breast implants following soaking in water and/or organic solvent (liquid).

The breast implants were analyzed to understand your potential exposure to chemicals.

Analysis for volatiles present in the shell and patch material showed that the shell contained up to 279µg of 1, 1, 1 trichloroethane and 251µg of isopropyl alcohol. Analysis for volatiles present in the gel was not necessary because the gel materials do not contain any organic solvents.

To assess for extractables, the shell and the gel components were separated for analysis. "Virgin shells" which contained the patch assembly and had been sterilized but not yet gel-filled were also analyzed. An analysis technique called exhaustive extraction was used. The highest level of extractable material was used when hexane, a non-polar solvent, was used for the extraction, and thus results with the hexane extracts are shown below. The concentrations of smaller molecular weight extractables, as shown below, were highly comparable to those present with FDA-approved saline-filled breast implants.

Identification	Gel (ppm)	Implant Shell and Patch (ppm)	Virgin Shell and Patch (ppm)
D3	ND (<146)	ND (<17)	ND (<7)
D4	ND (<69)	ND (<8)	ND (<3)
D5	ND (<6)	ND (<1)	ND (<1)
D6	ND (<6)	ND (<1)	ND (<1)
D7	ND (<6)	ND (<1)	ND (<1)
D8	ND (<8)	ND (<1)	ND (<1)
D9	ND (<8)	6	ND (<1)
D10	ND (<8)	12	2
D11	11	21	9
D12	32	94	26
D13	64	62	65
D14	237	186	209
D15	366	278	285
D16	491	351	317
D17	593	432	328
D18	729	527	342
D19	678	601	0
D20	735	605	212
D21	668	474	129
L1	ND (<63)	ND (<7)	ND (<3)
L2	ND (<8)	ND (<1)	ND (<1)
L3	ND (<8)	ND (<1)	ND (<1)
L4	ND (<10)	ND (<1)	ND (<1)
L5	ND (<8)	ND (<1)	ND (<1)
L6	ND (<7)	ND (<1)	ND (<1)
L7	ND (<8)	2	4
L8	ND (<8)	2	ND (<1)
L9	ND (<9)	8	ND (<1)
L10	19	17	ND (<1)
L11	35	29	ND (<1)
L12	63	49	ND (<1)
L13	103	84	ND (<1)
L14	132	108	ND (<1)
L15	169	128	ND (<1)
L16	183	106	ND (<1)
L17	161	137	ND (<1)
L18	177	128	ND (<1)
Diphenyl siloxanes	242	985	2762

ND (<X) = Not detected at less than X, the concentration in parts per million

Heavy Metal Analyses

Analyses were conducted on breast implants to determine your potential exposure to inorganic (metallic) elements. Any metallic elements not listed in the table were non-detectable.

Metal	Virgin Shell (standard dispersion) (ppm)	Virgin Shell (barrier dispersion) (ppm)	Patch (ppm)	Gel (ppm)
Antimony	ND (<0.1)	ND (<0.1)	ND (<0.1)	ND (<0.1)
Arsenic	ND (<0.1)	ND (<0.1)	ND (<0.1)	ND (<0.1)
Barium	1	1	2	1
Beryllium	ND (<0.1)	ND (<0.1)	ND (<0.1)	ND (<0.1)
Cadmium	ND (<0.1)	ND (<0.1)	ND (<0.1)	ND (<0.1)
Calcium	ND (<10)	ND (<10)	ND (<10)	ND (<10)
Chromium	0.3	0.4	1.8	0.2
Cobalt	ND (<0.2)	ND (<0.2)	ND (<0.2)	ND (<0.2)
Copper	ND (<0.1)	ND (<0.1)	ND (<0.1)	ND (<0.1)
Iron	ND (<0.1)	0.2	8.7	1.2
Lead	ND (<0.2)	ND (<0.2)	ND (<0.2)	0.3
Magnesium	ND (<10)	ND (<10)	ND (<10)	ND (<10)
Manganese	ND (<0.05)	ND (<0.05)	0.15	ND (<0.05)
Mercury	ND (<1)	ND (<1)	ND (<1)	ND (<1)
Molybdenum	ND (<0.5)	ND (<0.5)	ND (<0.5)	ND (<0.5)
Nickel	ND (<0.2)	1	0.7	ND (<0.2)
Potassium	ND (<1)	8	1	ND (<1)
Selenium	ND (<0.1)	ND (<0.1)	ND (<0.1)	ND (<0.1)
Silver	ND (<0.1)	0.2	ND (<0.1)	ND (<0.1)
Sodium	ND (<10)	ND (<10)	ND (<10)	ND (<10)
Thallium	ND (<1)	ND (<1)	ND (<1)	ND (<1)
Vanadium	ND (<0.4)	ND (<0.4)	ND (<0.4)	ND (<0.4)
Zinc	0.12	ND (<0.05)	3.9	0.22

ND (<X) = Not detected at less than X, the concentration in parts per million

In addition, catalyst metal analyses were carried out on the shell and gel components of the device. The shell and patch were found to contain 5.9 ppm of platinum, the patch was found to contain 6.6 ppm of tin, and the gel was found to contain 4.0 ppm of platinum. Platinum is a metal used as a catalyst in the manufacture of the shell and gel components of silicone breast implants. The small amounts of platinum remaining in the product following manufacturing may enter the body, either by diffusing through the intact shell (i.e., through gel bleed) or through an implant rupture. However, based on a review of the gel bleed testing, the published literature on the topic, as well as the

biocompatibility testing and clinical data on the device, FDA concluded that the platinum contained in breast implants is in the zero oxidation state, which has the lowest toxicity and, thus, does not pose a significant risk to women with silicone breast implants.

1.3 Who is eligible for **NATRELLE®** Silicone-Filled Breast Implants and **NATRELLE INSPIRA®** Breast Implants?

NATRELLE® Silicone-Filled Breast Implants and **NATRELLE INSPIRA®** Breast Implants have been approved for females for the following uses (procedures):

- Breast augmentation for women at least 22 years old. Breast augmentation includes primary breast augmentation to increase the breast size, as well as revision surgery to correct or improve the result of a primary breast augmentation surgery.
- Breast reconstruction. Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the result of a primary breast reconstruction surgery.

A separate patient document is available for those women considering breast reconstruction surgery and should be read prior to reaching a decision to undergo breast reconstruction.

1.4 Who Should not get Breast Implants (What are the Contraindications)?

A contraindication is a condition or circumstance that, if present, means a procedure should not be done. Contraindications for breast implant surgery are discussed in this section.

Breast implant surgery should not be performed in:

- Women with active infection anywhere in their body, because the implant will make the infection much harder to treat should the infection move into the breast.
- Women with existing cancer or pre-cancer of their breast who have not received adequate treatment for those conditions, because radiation and chemotherapy treatments may increase the risk of some complications seen with breast implants. Also, breast implants may interfere with radiation or chemotherapy treatments.
- Women who are currently pregnant or nursing, because surgery may interfere with the safety of the pregnancy/nursing. Since breast augmentation is an elective surgery, it should be postponed until you are no longer pregnant or nursing.

1.5 Precautions

A precaution is information that warns the reader of a potentially hazardous situation which, if not avoided, may result in minor or moderate injury. The following are precautions; safety and effectiveness have not been established in patients with these conditions:

- Autoimmune diseases (for example, lupus and scleroderma)
- A weakened immune system (for example, currently taking drugs that weaken the body's natural resistance to disease)
- Planned chemotherapy following breast implant placement
- Planned radiation therapy to the breast following breast implant placement
- Conditions that interfere with wound healing and blood clotting
- Reduced blood supply to breast tissue
- Clinical diagnosis of depression or other mental health disorders, including body dysmorphic disorder and eating disorders. Please discuss any history of mental health disorders with your surgeon prior to surgery. Patients with a diagnosis of depression, or other mental health disorders, should wait until these conditions have resolved or stabilized prior to undergoing breast implantation surgery.

1.6 Warnings

Warnings are statements that alert the reader about a situation which, if not avoided, could result in serious injury or death. Please take the time to read this entire document before having breast implant surgery. This is important so that you will understand the risks and benefits and have realistic expectations of the outcome of your surgery. Breast implants are associated with many short-term and long-term risks.

There is a boxed warning for breast implants. [Please see the cover page.](#)

WARNING – Be aware that many of the changes to your breast following implantation cannot be reversed. If you later choose to have your implant(s) removed and not replaced, you may experience unacceptable dimpling, puckering, wrinkling, or other cosmetic changes to the breast, which can be permanent.

WARNING – Before you decide to have breast implant surgery, you should know that breast implants are not lifetime devices, and breast implantation is likely not a one-time surgery. The longer implants are in place, the greater the potential risk for complications. In the event of complications or unacceptable cosmetic outcomes, you will likely need additional unplanned surgeries on your augmented breasts. These additional surgeries can include implant removal or replacement, or other surgical procedures. Later surgeries to replace implants (revision-augmentation) carry higher risks of complications than the first (primary) augmentation surgery. Therefore, you should also consider the complication rates for revision-augmentation since you may experience these risks in the future.

WARNING – Your **NATRELLE**[®] Silicone-Filled Breast Implants or **NATRELLE INSPIRA**[®] Breast Implants may rupture without any symptoms (silent rupture). This means that neither you nor your surgeon will know that your implants have ruptured.

It is recommended that you have periodic imaging (e.g. MRI, ultrasound) of your silicone gel filled breast implants to screen for implant rupture regardless of whether your implants are for cosmetic augmentation or reconstruction. These recommendations do not replace other additional imaging that may be required depending on your medical history or circumstances (i.e., screening mammography for breast cancer.) Even if you have no symptoms, you should have your first ultrasound or MRI at 5-6 years after your initial implant surgery and then every 2-3 years thereafter. If you have symptoms at any time or uncertain ultrasound results for breast implant rupture, an MRI is recommended.

2.0 BREAST IMPLANT BENEFITS AND RISKS

Undergoing any type of surgical procedure involves risks such as the effects of anesthesia, infection, swelling, redness, bleeding, pain, and even death. Some of these risks are serious, and all of these risks need to be balanced against the benefits of the surgery itself. These benefits and risks of breast implants are described below. At the end of this document is a list of published studies used to gather the information discussed in the sections below. These studies may be helpful to you if you wish to learn more about a specific complication or condition. The reference list is not complete because studies are being conducted all the time. Your physician may have other resources for further reading. The information provided below focuses on women undergoing Primary Augmentation and Revision-Augmentation with **NATRELLE**[®] Silicone-Filled Breast Implants or **NATRELLE INSPIRA**[®] Breast Implants. The studies in the list of references also include women undergoing breast reconstruction and other types of implants from a variety of manufacturers. The risks and benefits of breast reconstruction may differ from those of augmentation, and the risks of other types of implants may differ from those of **NATRELLE**[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®] Breast Implants.

2.1 What Are the Benefits?

Breast augmentation can change the size and proportion of the breast(s). In addition, revision-augmentation (replacement of an existing breast implant) can correct or improve the result of a primary augmentation surgery.

Breast augmentation has the potential to offer both physical and psychological benefits to women.¹ The benefits of breast implants, therefore, relate to their ability to enhance breast volume and attain body symmetry.^{1,3,5} Many studies have reported that a majority of breast augmentation patients are satisfied with the results of their surgery. In Allergan's Core Study through 10 years, approximately 9 out of 10 women undergoing primary augmentation or revision-augmentation with **NATRELLE**[®] Silicone-Filled Breast Implants are satisfied with their breast implants. [Section 5.3](#) provides more information on benefits seen in Allergan's Core Study.

2.2 What Are the Potential Risks?

[Table 1](#) describes some of the known risks of breast augmentation along with possible effects of those risks. This information is based on the results of Allergan's Core Study of 455 Primary Augmentation patients and 147 Revision-Augmentation patients. The Allergan Core Study assessed both BIOCELL textured and smooth breast implants. BIOCELL textured breast implants were recalled in July 2019 for their higher risk associated with BIA-ALCL and are no longer manufactured or marketed. Additional useful information related to these risks as well as risks occurring in less than 1% of patients in the Core Study is provided following [Table 1](#). [Sections 5.4](#) through [5.7](#) as well as [Tables 2](#) and [3](#) provide more information on risks seen in Allergan's Core Study.

Table 1
Risks of Breast Augmentation Through 10 Years with NATRELLE®
Silicone-Filled Breast Implants

Event	Likelihood of Event Occurring in Primary Augmentation Patients ^a	Likelihood of Event Occurring in Revision-Augmentation Patients ^a	Possible Resulting Effects of the Event
Key Risks			
Additional Surgeries (Reoperations)	36 out of 100 patients (36%)	46 out of 100 patients (46%)	<ul style="list-style-type: none"> • Infection • Scarring • Hematoma or Seroma • Delayed wound healing • Necrosis • Pain or Discomfort • Anesthesia-related complications • Loss of breast tissue • Undesirable cosmetic result
Implant Removal with Replacement	19 out of 100 patients (19%)	30 out of 100 patients (30%)	<ul style="list-style-type: none"> • Infection • Scarring • Hematoma or Seroma • Delayed wound healing • Necrosis • Pain or Discomfort • Anesthesia-related complications • Loss of breast tissue • Undesirable cosmetic result
Implant Removal without Replacement	3 out of 100 patients (3%)	4 out of 100 patients (4%)	<ul style="list-style-type: none"> • Infection • Scarring • Hematoma or Seroma • Delayed wound healing • Necrosis • Pain or Discomfort • Anesthesia-related complications • Loss of breast tissue • Undesirable cosmetic result
Capsular Contracture (Baker Grade III/IV)	19 out of 100 patients (19%)	29 out of 100 patients (29%)	<ul style="list-style-type: none"> • Pain or Discomfort • Breast hardness/firmness • Reoperation • Implant removal
Rupture	MRI Cohort	9 out of 100 patients (9%)	<ul style="list-style-type: none"> • Implant Removal
	Non-MRI Cohort	14 out of 100 patients (14%)	
Other Risks Occurring in 1% or more of Patients			
Breast Pain	12 out of 100 patients (12%)	12 out of 100 patients (12%)	<ul style="list-style-type: none"> • Resulting effects are contingent on underlying cause(s)
Swelling	9 out of 100 patients (9%)	8 out of 100 patients (8%)	<ul style="list-style-type: none"> • Pain or discomfort • Resulting effects are contingent on underlying cause(s)

Event	Likelihood of Event Occurring in Primary Augmentation Patients ^a	Likelihood of Event Occurring in Revision-Augmentation Patients ^a	Possible Resulting Effects of the Event
Implant Malposition	7 out of 100 patients (6%)	6 out of 100 patients (6%)	<ul style="list-style-type: none"> • Implant visibility • Asymmetry • Reoperation • Implant removal
Nipple Complications	6 out of 100 patients (6%)	1 out of 100 patients (1%)	<ul style="list-style-type: none"> • Increased or decreased nipple sensitivity • Breastfeeding difficulties • May affect sexual response
Hypertrophic/ Other Abnormal Scarring	4 out of 100 patients (4%)	7 out of 100 patients (7%)	<ul style="list-style-type: none"> • Scar revision procedure (reoperation) • Undesirable cosmetic result
Asymmetry	3 out of 100 patients (3%)	7 out of 100 patients (7%)	<ul style="list-style-type: none"> • Undesirable cosmetic result • Reoperation • Implant removal
Implant Palpability/ Visibility	2 out of 100 patients (2%)	6 out of 100 patients (6%)	<ul style="list-style-type: none"> • Undesirable cosmetic result • Reoperation • Implant removal
Seroma/Fluid Accumulation	2 out of 100 patients (2%)	6 out of 100 patients (6%)	<ul style="list-style-type: none"> • Swelling • Pain or Discomfort • Infection • Incision and drainage (reoperation) • Implant removal
Ptosis	2 out of 100 patients (2%)	5 out of 100 patients (5%)	<ul style="list-style-type: none"> • Undesirable cosmetic result • Wrinkling/rippling • Reoperation • Implant removal
Wrinkling/ Rippling	2 out of 100 patients (2%)	5 out of 100 patients (5%)	<ul style="list-style-type: none"> • Discomfort • Undesirable cosmetic result • Reoperation • Implant removal
Hematoma	2 out of 100 patients (2%)	2 out of 100 patients (2%)	<ul style="list-style-type: none"> • Swelling • Pain or Discomfort • Infection • Incision and drainage (reoperation) • Implant removal
Changes in Breast Sensation	2 out of 100 patients (2%)	2 out of 100 patients (2%)	<ul style="list-style-type: none"> • Increased or decreased breast sensitivity • Breastfeeding difficulties • May affect sexual response
Delayed Wound Healing	1 out of 100 patients (1%)	1 out of 100 patients (1%)	<ul style="list-style-type: none"> • Increase risk of infection, extrusion, or necrosis

^a Based on the results of the Allergan Core Clinical Study for the first 10 years after implant surgery. There were 455 Primary Augmentation patients and 147 Revision-Augmentation patients enrolled.

- **Additional Surgeries (Reoperations)**

You should assume that you will need to have additional surgeries (reoperations). In Allergan's Core Study, approximately 36 out of every 100 women (36%) undergoing primary augmentation and 46 out of every 100 women (46%) undergoing revision-augmentation had 1 or more reoperation. Approximately 9 out of every 100 women (9%) undergoing primary augmentation and 18 out of every 100 women (18%) undergoing revision-augmentation had 2 or more reoperations. The costs of additional surgeries may not be covered by insurance.

Patients may decide to change the shape or type of their implants, requiring additional surgery. In addition, problems such as rupture, capsular contracture, hypertrophic scarring (irregular, raised scar), asymmetry, infection, and shifting can require additional surgery. Reoperation increases the risk of certain complications, such as rupture, capsular contracture, and infection. [Section 5.5](#) provides more information on reoperations reported in Allergan's Core Study.

- **Implant Removal**

Because these are not lifetime devices, the longer you have your implants the more likely it will be for you to have them removed for any reason, either because of dissatisfaction, an unacceptable cosmetic result, or a complication such as capsular contracture. In Allergan's Core Study, approximately 21 out of every 100 women (21%) undergoing primary augmentation and 32 out of every 100 women (32%) undergoing revision-augmentation had their implants removed. Approximately 9 out of 10 removed implants are replaced with new implants, which can increase the risk of capsular contracture or reoperation. Removing implants without replacing them can result in dimpling, puckering, wrinkling, or other cosmetic changes in the breast. These changes can be permanent.

Even if you have your implants replaced, implant removal may result in loss of your breast tissue. Also, implant replacement increases your risks of future complications. For example, the risks of capsular contracture and reoperation increase for patients with implant replacement compared to first time placement. You should consider the possibility of having your implants replaced and its consequences when making your decision to have implants. [Section 5.6](#) provides more information on implant removals reported in Allergan's Core Study.

- **Capsular Contracture**

The scar tissue (capsule) that normally forms around the implant may tighten over time and compress the implant, making it feel firm and leading to what is called capsular contracture. Capsular contracture may be more common following infection, hematoma, and seroma, and the chance of it happening may increase over time. Capsular contracture occurs more commonly in revision-augmentation than in primary augmentation. Because you may have your initial implants replaced, you should be aware that your risk of capsular contracture increases with revision-augmentation. Capsular contracture is a risk factor for implant rupture, and it is a common reason for reoperation.

Symptoms of capsular contracture range from mild firmness and mild discomfort to severe pain, distorted shape of the implant, and palpability (ability to feel the implant). Capsular contracture is graded into 4 Baker Grade levels depending on its severity:

- o Baker Grade I – Normally soft and natural appearance
- o Baker Grade II – A little firm, but breast looks normal
- o Baker Grade III – More firm than normal, and may look abnormal (change in shape)
- o Baker Grade IV – Hard, obvious distortion, and tenderness with pain

Baker Grades III and IV are considered severe, and often additional surgery is needed to correct these grades. Additional surgery may be needed in cases where pain and/or firmness are severe. This surgery ranges from removal of the implant capsule tissue to removal and possible replacement of the implant itself. This surgery may result in loss of your breast tissue. Capsular contracture may happen again after these additional surgeries.

- **Rupture**

An implant rupture is caused by a hole or tear in the shell of the implant that allows silicone gel filler material to leak from the shell. Ruptures can be intracapsular (inside the scar tissue capsule surrounding the implant) or extracapsular (outside the scar tissue surrounding the implant). All women should have regular ultrasound or MRI examinations to detect silent rupture. All women who have ruptured implants should have the implants and any gel removed. With **NATRELLE®** Silicone-Filled Breast Implants and **NATRELLE INSPIRA®** Breast Implants, silicone rarely migrates outside of the scar tissue capsule. Further information on rupture is provided in [Section 2.3](#), and information on rupture reported in Allergan's Core Study is provided in [Section 5.7](#).

- **Unsatisfactory Results**

Unsatisfactory results such as wrinkling, asymmetry, implant displacement (shifting), incorrect size, unanticipated shape, implant palpability, scar deformity, hypertrophic scarring and/or implant malposition, may occur. Some of these results may cause discomfort. Pre-existing asymmetry may not be entirely correctable by implant surgery. Revision surgery may be recommended to maintain patient satisfaction but carries additional considerations and risks. Selecting an experienced plastic surgeon may minimize, but not necessarily prevent, unsatisfactory results.

In Allergan's Core Study the most common unsatisfactory result was implant malposition. Approximately 2 out of 100 women (2%) who underwent primary augmentation had additional surgery to improve implant malposition. Approximately 3 out of 10 reoperations for women who underwent primary augmentation were to improve unsatisfactory cosmetic results.

- **Pain**

Pain of varying intensity and length of time may occur and persist following breast implant surgery. In addition, improper size, placement, surgical technique, or capsular contracture may result in pain. In a European study through 5 years, approximately 1 out of every 100 women with any breast implant had breast pain lasting longer than 3 months.¹⁵ Tell your surgeon about significant pain or if pain persists.

- **Changes in Nipple and Breast Sensation**

Feeling in the nipple and breast can increase or decrease after implant surgery. The range of changes varies from intense sensitivity to no feeling in the nipple or breast following surgery. While some of these changes can be temporary, they can also be permanent, and may affect your sexual response or your ability to nurse a baby.

- **Infection**

Infection can occur with any surgery or implant. Most infections resulting from surgery appear within a few days to weeks after the operation. However, infection is possible at any time after surgery. In addition, breast and nipple piercing procedures may increase the possibility of infection. Infections in tissue with an implant present are harder to treat than infections in tissue without an implant. If an infection does not respond to antibiotics, the implant may have to be removed, and another implant may be placed after the infection is resolved (cleared up). As with many other surgical procedures, in rare instances, toxic shock syndrome has been noted in women after breast implant surgery, and it is a life-threatening condition. Symptoms include sudden fever, vomiting, diarrhea, fainting, dizziness, and/or sunburn-like rash. You should contact a doctor immediately for diagnosis and treatment if you have these symptoms.

- **Delayed Wound Healing**

Some patients may experience a prolonged wound healing time. Delayed wound healing may increase the risk of infection, extrusion, and necrosis. Smoking may interfere with the healing process. You should contact your surgeon immediately if your wound does not heal within the period of time he/she has discussed with you.

- **Hematoma/Seroma**

Hematoma is a collection of blood within the space around the implant, and a seroma is a build-up of fluid around the implant. Having a hematoma and/or seroma following surgery may result in infection and/or capsular contracture later on. Symptoms from a hematoma or seroma may include swelling, pain, and bruising. If a hematoma or seroma occurs, it will usually be soon after surgery. However, this can also occur at any time after injury to the breast. While the body absorbs small hematomas and seromas, some will require surgery, typically involving draining and potentially placing a surgical drain in the wound temporarily for proper healing. A small scar can result from surgical draining. Implant rupture also can occur from surgical draining if there is damage to the implant during the draining procedure.

- **Breastfeeding**

Breastfeeding difficulties have been reported following breast surgery, including breast reduction and breast augmentation. A periareolar incision (an incision around the colored portion surrounding the nipple) may increase the likelihood of problems with breastfeeding. The most common breastfeeding problem is inadequate milk production. [Section 5.7](#) provides more information on breastfeeding complications reported in Allergan's Core Study.

- **Calcium Deposits in the Tissue Around the Implant**

Calcium deposits can form in the tissue capsule surrounding the implant. Symptoms may include pain and firmness. Deposits of calcium can be seen on mammograms and can be mistaken for possible cancer, resulting in additional surgery for biopsy and/or removal of the implant to distinguish calcium deposits from cancer. If additional surgery is necessary to examine and/or remove calcifications, this may cause damage to the implants. Calcium deposits also occur in women who undergo breast reduction procedures, in patients who have had hematoma formation, and even in the breasts of women who have not undergone any breast surgery. The occurrence of calcium deposits increases significantly with age.

- **Extrusion**

Extrusion is when the breast implant comes through your skin. This may occur, for example, when your wound has not closed or when breast tissue covering your implants weakens. Radiation therapy might increase the likelihood of implant extrusion. Most women with extrusion need to have their implant removed. Extrusion requires additional surgery and removal of the implant which may result in additional scarring and/or loss of your breast tissue.

- **Necrosis**

Necrosis is the death of cells or tissues. This may prevent or delay wound healing and require surgical correction, which may result in additional scarring and/or loss of your breast tissue. Implant removal may also be necessary. Infection, steroid use in the surgical pocket, smoking, chemotherapy, radiation, and excessive heat or cold therapy may increase the likelihood of necrosis.

- **Delayed Wound Healing**

Some patients may experience a prolonged wound healing time. Delayed wound healing may increase the risk of infection, extrusion, and necrosis. Smoking may interfere with the healing process. You should contact your surgeon immediately if your wound does not heal within the period of time he/she has discussed with you.

- **Breast Tissue Atrophy/Chest Wall Deformity**

The pressure of the breast implant may cause breast tissue thinning (with increased implant visibility and palpability) and chest wall deformity. This can occur while implants are still in place or following implant removal without replacement. The likelihood of breast tissue atrophy or chest wall deformity is unknown in women undergoing primary augmentation or revision-augmentation. Either of these conditions may result in additional surgeries and/or unacceptable dimpling/puckering of the breast.

- **Lymphadenopathy**

Lymphadenopathy is a chronic enlargement of the lymph nodes. A lymph node is a round mass of tissue which makes cells as part of your immune system. The lymph nodes in the armpit (axilla) drain the breast area of fluid. Some patients with breast implants report having enlarged lymph nodes in the armpit(s). Sometimes the enlarged lymph nodes are painful. If they become too large or painful, the lymph node(s) may need to be surgically removed. Painful and/or enlarged lymph nodes should be reported to your doctor. Lymphadenopathy has been associated with tissue reactions, granulomas, and silicone at the lymph nodes of women with intact and ruptured silicone breast implants.⁸¹

- **Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)**

If you have breast implants you have a very small, but increased risk of developing breast implant associated anaplastic large cell lymphoma, or BIA-ALCL. BIA-ALCL is not breast cancer — it is a rare type of non-Hodgkin's lymphoma (cancer of the immune system). In most cases, BIA-ALCL is found in the scar tissue and fluid near the implant, but in some cases, it can spread throughout the body. In the cases that have spread beyond the scar tissue and fluid near the implant, rare cases of death have been reported.

Most patients were diagnosed with BIA-ALCL when they sought medical treatment for implant-related symptoms such as swelling, pain, lumps, or asymmetry that developed after their initial surgical sites were fully

healed. In the cases known to FDA to date, BIA-ALCL was diagnosed years after the breast implant was placed. The earliest report was less than one year after implant placement and the latest was 34 years after the implant surgery. About half the cases occurred within the first 8 years after implant. BIA-ALCL was most often diagnosed in women who had textured implants, as of the August 20, 2020 FDA report. The textured implant may have been placed at the most recent surgery or at any other prior breast implant operation.

If you develop swelling or pain around your breast implants, be sure to talk to your health care provider. Your health care provider should consider the possibility of BIA-ALCL if, after you have recovered from your breast implant operation, you later notice changes in the way your breast looks or feels — including swelling or pain around the implant. If your health care provider suspects BIA-ALCL, they will refer you to an appropriate specialist for evaluation which may involve obtaining fluid and some tissue samples from around your breast implant. If a diagnosis of BIA-ALCL is confirmed, the doctor will develop an individualized treatment plan for you. Because of the small number of cases worldwide and the variety of available treatment options, there is no single defined treatment. However, if you are diagnosed with BIA-ALCL, the National Comprehensive Cancer Network (NCCN) recommends removing the implant and the surrounding tissue.

If you have breast implants you should monitor them and follow your routine medical care. You do not need to take any additional steps. It is not necessary to remove your breast implants if you have no symptoms without a diagnosis of BIA-ALCL.

If you are diagnosed with BIA-ALCL, you can help the FDA understand the disease and effectiveness of treatment.

You or your doctor should report all confirmed cases of BIA-ALCL to the FDA (<https://www.fda.gov/Safety/MedWatch/>). In some cases, the FDA may contact you for additional information. The FDA will keep the identities of the reporter and the patient confidential.

In addition, if you are diagnosed with BIA-ALCL, talk to you doctor about reporting it to the PROFILE Registry (<https://www.theptf.org/research/clinical-impact/profile.htm>). Every case of BIA-ALCL should be reported to the PROFILE Registry because this helps provide a better understanding of the disease.

If you are considering breast implant surgery, you should discuss the risks and benefits with your health care provider. You may also visit the FDA's Breast Implants website for additional information www.fda.gov/medical-devices/breast-implants/risks-and-complications-breast-implants.

For additional information on FDA's analysis and review of BIA-ALCL, please visit:

www.fda.gov/medical-devices/breast-implants/questions-and-answers-about-breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl.

2.3 What Causes Breast Implants to Rupture and How Can I Tell if My Implants Are Ruptured?

Breast implants are not lifetime devices. Breast implants rupture when the shell develops a tear or hole. Your breast implants can rupture any time after they are implanted, but they are more likely to rupture the longer you have them. The following things may cause your implant to rupture: damage by surgical instruments, stressing the implant during implantation which may weaken it, folding or wrinkling of the implant shell, excessive force to the chest (for example, during closed capsulotomy, which is contraindicated), trauma, compression during mammographic imaging, and severe capsular contracture. Breast implants may also simply wear out over time.

If a device rupture is found, Allergan conducts laboratory studies to determine the cause of the rupture, such as damage during surgery, or a “wear-out” of the device. These studies include a comprehensive visual and microscopic inspection of the shell, including a measurement of shell thickness, and observation of various characteristics near the rupture location as well as in the entire shell. Mechanical testing of the implant shell may also be performed to better determine the cause of an observed rupture. There may still be unidentified causes of rupture. These laboratory studies will continue to try to identify any additional causes of rupture.

When the shell of a breast implant develops a tear or hole, the silicone gel inside **NATRELLE**[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®] Breast Implants tends to stay in place, making ruptures especially difficult to detect. This means that most of the time neither you nor your plastic surgeon will know if your breast implant has a tear or hole, called a silent rupture. In fact, a plastic surgeon who is familiar with breast implants is likely to detect less than 3 out of every 10 ruptured silicone-filled breast implants by physical examination.⁷ The best method to identify a silent rupture is currently MRI examination. MRI examination can detect about 9 out of every 10 ruptured silicone breast implants.⁸ It is recommended that you have period imaging (e.g. MRI, ultrasound) of your silicone gel filled breast implants to screen for implant rupture regardless of whether your implants are for cosmetic augmentation or reconstruction. These recommendations do not replace other additional imaging that may be required depending on your medical history or circumstances (i.e., screening mammography for breast cancer.) Even if you have no symptoms, you should have your first ultrasound or MRI at 5-6 years after your initial implant surgery and then every 2-3 years thereafter. If you have symptoms at any time or uncertain ultrasound results for breast implant rupture, an MRI is recommended.

The cost of these image screenings may exceed the cost of your initial surgery over your lifetime. This cost may not be covered by your insurance, so you should take it into account when deciding to have breast augmentation.

Sometimes there are symptoms associated with gel implant rupture. If your implants rupture, you may notice hard knots or lumps surrounding the implant or in the armpit, your breast or the implant may change shape or get smaller, or you may notice pain, tingling, swelling, numbness, burning, or hardening of the breast. If you have any of these symptoms, you should have an MRI to determine if your implants have ruptured.^{1,9}

If you have an MRI or ultrasound that shows signs of rupture, or if your surgeon determines you have signs or symptoms of rupture, he or she will talk with you about your options. As a precaution, Allergan recommends that ruptured implants be taken out permanently and either replaced with a new implant or not replaced, depending on your preference or medical need.

There are also consequences of rupture. If your implants rupture, the silicone gel may remain within the scar tissue capsule around the implant. The silicone gel may also move outside the capsule or it may move beyond the breast (gel migration). The silicone gel from a ruptured implant may begin inside the capsule and progress outside the capsule through gel migration if it is not removed. Ruptured implants might also have consequences on your health. More information on these consequences, as reported in the literature, is included below.

In Allergan's Core Study, a group of patients had scheduled MRIs to look for rupture independent of whether or not they had any symptoms. These patients are called the MRI cohort. The remaining patients did not have scheduled MRIs to look for rupture. They are called the non-MRI cohort. The rupture rate for the whole MRI cohort in the Allergan's Core Study (including augmentation, revision-augmentation, reconstruction, and revision-reconstruction patients) through 10 years was 13.0% for patients and 7.7% for implants. For the non-MRI cohort, the rupture rate through 10 years was 9.5% for patients and 5.6% for implants. Rupture rates are presented by patient and by implant as some patients may experience rupture in both implants. Across all patients in the Allergan's Core Study, all ruptures were intracapsular with the exception of 3 cases of extracapsular gel (one rupture progressed to extracapsular gel following exploratory surgery to confirm the rupture and then implant replacement was delayed). There were no cases of migrated gel.

Additional information on the likelihood that your **NATRELLE®** Silicone-Filled Breast Implants or **NATRELLE INSPIRA®** Breast Implants will rupture comes from a published European study known as the International MRI Study.⁶ Silent rupture data were collected via a single MRI on 77 augmentation, 11 reconstruction, and 18 revision patients implanted with smooth and textured **NATRELLE®** Silicone-Filled Breast implants by 5 surgeons. The average age of the implants was approximately 11 years. Silent rupture was found in approximately 15% of the combined group of augmentation, reconstruction, and revision patients and 8% of the implants. There was one possible case of extracapsular rupture with the remainder classified as intracapsular ruptures. No cases of gel migration were found.

Additional information on rupture will be collected through Allergan's post-approval study called the Breast Implant Follow-Up Study (BIFS).

Additional Information on Consequences of Rupture from Literature

Below is a summary of information related to the health consequences of implant rupture. Keep in mind some doctors and scientists disagree as to the validity of some of these reports. These reports were in women who had implants from a variety of manufacturers and implant models.

- Ruptured breast implants have been associated with breasts becoming hard, changing shape or size, and becoming painful.⁹ These symptoms are not specific to rupture, as they also are experienced by women who have capsular contracture.
- There have been rare reports of the silicone gel from implants moving to nearby locations such as the chest wall, armpit, or upper abdominal wall, and even as far as the arm or the groin. This migrating gel has damaged nerves, formed granulomas, and/or broken down tissues in direct contact with the gel in a few cases. There have been reports of silicone in the liver of women with silicone breast implants. Silicone gel material has moved to lymph nodes in the armpit, even in women whose implants did not appear to have ruptured, leading to lymphadenopathy.⁸¹
- Concerns have been raised that women with ruptured implants are more likely to develop connective tissue disease, rheumatic disease, fatigue, or fibromyalgia.^{16,19,35,36} To determine if these diseases are related to ruptured implants, a number of studies have evaluated many women with breast implants. Only one small study distinguished between women with ruptured or intact implants.¹⁹ Most doctors and researchers agree that there is no evidence that ruptured implants or migrated gel causes any disease that affects the whole body (systemic disease) like Connective Tissue Disease (CTD) or cancer.

2.4 What Are Other Reported Conditions?

Patients receiving breast implants have reported a variety of signs and symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases and others. Individual patient risk for developing these symptoms has not been well-established. Some patients report complete resolution of symptoms when the implants are removed without replacement.

There have been reports of women with silicone gel-filled breast implants developing other conditions. The relationships between many of these conditions and breast implants have been studied and are discussed below. Furthermore, there may be unknown risks associated with breast implants.

- **Connective Tissue Disease (CTD)**

Connective tissue diseases include diseases such as lupus, scleroderma, rheumatoid arthritis and fibromyalgia. Some scientific evidence published

from 1988 to 2007 supports the conclusion that there is no increased risk of connective tissue disease or autoimmune disorders for women with silicone gel breast implants.^{1,16-23,25-29,31,33,34,36,37,39} Some independent scientific panels and review groups (1988-2016) have also concluded that the weight of the evidence shows no relationship between breast implants and connective tissue disease, or at least if a risk cannot be absolutely excluded, it is too small to be measured.^{1,16,18,20,24,25,30, 28, 32-36}

- **CTD Signs and Symptoms**

Some women (even without breast implants) may have some of the signs or symptoms of connective tissue diseases, without having the actual disease. Patients receiving breast implants have reported a variety of signs and symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases and others. Individual patient risk for developing these symptoms has not been well-established. Some patients report complete resolution of symptoms when the implants are removed without replacement.

Some panels of expert scientists and literature reports published between 2000 and 2004 have found no evidence that silicone breast implants cause a consistent pattern of CTD signs and symptoms.^{1,38-41} Having these CTD signs and symptoms does not necessarily mean you have a connective tissue disease; however, you should be aware that you may experience these signs and symptoms after undergoing breast implantation. If you notice an increase in these signs or symptoms, you should consider seeing a rheumatologist to determine whether these signs or symptoms are due to a connective tissue disorder or autoimmune disease.

- **Cancer**

Breast Cancer – Reports in the medical literature (1995-2004) indicate that breast implants do not increase the risk for developing breast cancer.^{42,45,47,55,65} Some reports have suggested that breast implants may make it harder to detect breast cancer by mammography and/or biopsy. Other reports (2000-2004) indicate that breast implants do not delay breast cancer detection, nor do they decrease cancer survival of women with breast implants.^{42,48,56,64,65} A large follow-up study published in 2001 reported no evidence that breast implants are associated with cancer, and even showed that women with breast implants had less breast cancer than the general population.⁵⁵

Brain cancer – Most studies of brain cancer published between 2000 and 2007 in women with silicone gel breast implants have found no increased risk.^{44,49,53,62,63,65} One study published in 2001 has reported a higher incidence rate of brain cancer in women with breast implants as compared to the general population.⁴³ However, rates of brain cancer were not significantly higher in women with breast implants when compared to women who had other non-breast implant plastic surgery. The data from 4 large studies of women with breast implants and a long-term follow-up study published in 2004 concluded that breast implants are not associated with brain cancer.⁶¹

Respiratory/lung cancer – Several studies published between 2000 and 2006 have found that women with silicone gel breast implants are not at greater risk for lung cancer.^{44,53,62,63,65} Studies published between 2001 and 2007 have reported an increased incidence of respiratory/lung cancer in women with breast implants.^{43,49,55} However, the risk of lung cancer was not higher than national lung cancer rates for the general population. Other studies published between 1997 and 2003 of women in Sweden and Denmark have found that women who get breast implants are more likely to be current smokers than women who get breast reduction surgery or other types of cosmetic surgery.^{46,54,57} Therefore, the increased incidence of respiratory/lung cancer could be due to smoking rather than breast implants.

Cervical/vulvar cancer – Most studies (2000- 2006) found that women with silicone gel breast implants have no greater risk of cervical/vulvar cancers than women without implants.^{44,53,62,63,65} Two studies (2001 and 2007) reported an increased incidence of cervical/vulvar cancer in women with breast implants.^{43,49}

Other cancers – Studies published between 2000 and 2007 have examined other types of cancer including eye, urinary tract, connective tissue, and endocrine system. These studies showed that women with silicone gel breast implants have no greater risk of these types of cancers compared to the general population.^{24,39,43,44,49,53,62,63} A large, long-term study published in 2004 found that women with breast implants were not at greater risk for a wide variety of cancers, including stomach cancer and leukemia.³⁹ In Allergan's Core Study, there were patients who developed cancer after implantation.

Cancer Screening – With breast implants, routine screening mammography for breast cancer will be more difficult. If you are of the proper age for mammography screening, you should continue to undergo routine mammography for screening as recommended by your primary care physician. More x-ray views are necessary for women with breast implants; therefore, you will receive more exposure to radiation. However, the benefit of having the mammogram to find cancer outweighs the risk of the additional x-rays. Be sure to inform the mammography technologist that you have implants. The technologist can then use special techniques to get the best possible views of your breast tissue.

- **Neurological Disease, Signs, and Symptoms**

Some women with breast implants have complained of neurological symptoms (such as difficulties with vision, sensation, muscle strength, walking, balance, thinking or remembering things) or diseases (such as multiple sclerosis), which they believe are related to their implants. A panel of expert scientists (Institute of Medicine, 2000) found that the evidence linking neurological diseases with breast implants is insufficient or flawed.¹ Other researchers published more evidence that silicone gel breast implants do not cause neurological diseases or symptoms in 2001.^{1,66,67}

- **Suicide**

Some studies published between 2001 and 2007 showed that women with breast implants were more likely to commit suicide than women without breast implants, but it is not clear whether these suicides were associated with having silicone gel breast implants or an underlying condition that can lead to suicide, depression, and/or anxiety.^{43,68,69,71-76} One researcher believes that some women who want cosmetic surgery suffer from a disorder, called body dysmorphic disorder, which may cause them to think about suicide or attempt suicide.⁷⁰

The strongest predictor for suicide is having been hospitalized for any psychiatric condition. One study published in 2004 found that women with breast implants had higher rates of hospital admission due to psychiatric causes prior to surgery, as compared with women who had breast reduction or in the general population of Danish women.⁷⁴ This may be a contributing factor to the reported higher incidence of suicide in women with breast implants.

- **Effects on Children**

At this time, doctors do not know if a small amount of silicone passes through the silicone shell of breast implants into breast milk during breastfeeding. Although doctors cannot accurately measure silicone levels in breast milk, silicon (one component in silicone) levels were not higher in breast milk from women with silicone gel-filled implants than in breast milk from women without implants.

In addition, questions have been raised about whether breast implants can have damaging effects during pregnancy. Two studies published in 2001 and 2002 in humans have found that children born to women with breast implants did not have an increased risk of birth defects.^{79,80} A third study, published in 2004, looked at low birth weight and did not find an elevated risk.⁷⁸ A review published in 2007 including many women found that children of women with breast implants are not at increased risk for birth defects.² Overall, there is no evidence from studies published between 2000 and 2007 that shows silicone gel breast implants have any harmful effects on the children of implanted women.^{1,2,77,78-80}

- **Potential Health Consequences of Gel Bleed**

Small quantities of low molecular weight silicone compounds, as well as platinum, have been found to leak through an intact implant shell. This is called gel bleed.^{1,83} The evidence is mixed as to whether gel bleed can affect your health. For instance, studies published in 2000 and 2005 on implants implanted for a long time suggested that gel bleed may contribute to capsular contracture¹ and lymphadenopathy.⁸¹ However, saline-filled breast implants have similar or higher rates of capsular contracture and other complications. Because saline-filled breast implants do not contain silicone gel, gel bleed cannot cause these complications in women with saline-filled breast implants, and might not cause these complications in women with silicone gel-filled breast implants.

Furthermore, the silicone material used in Allergan's implants did not cause toxic reactions when large amounts were placed in test animals. There is little platinum contained in breast implants, and studies published between 1987 and 1999 have shown that it is in the safest state.^{82,84,85,87}

Allergan performed a laboratory test to analyze the silicones and platinum (used in the manufacturing process), which may diffuse out of intact implants into the body. Over 99% of the low molecular weight silicones and platinum stayed in the implant. The overall body of evidence supports that gel bleed is minimal and has no health consequences.

3.0 SURGICAL CONSIDERATIONS FOR BREAST AUGMENTATION

3.1 What are the Alternatives to Breast Augmentation with *NATRELLE*[®] Silicone-Filled Breast Implants or *NATRELLE INSPIRA*[®] Breast Implants?

For primary augmentation patients, alternatives may include:

- Accepting your breasts as they are and having no surgery
- Wearing a padded bra or external prostheses
- Having mastopexy surgery (breast lift) without an implant
- Having surgery with saline implants

For revision-augmentation patients, alternatives may include:

- No revision
- Removal with:
 - No replacement
 - A padded bra or external prostheses
 - Replacement using saline implants

3.2 What Are Questions to Consider When Choosing a Surgeon?

When choosing a surgeon who is experienced with breast augmentation, you should find out the answers to the following questions:

- How many breast augmentation implantation procedures does he/she perform per year?
- How many years has he/she performed breast augmentation procedures?
- What types of implants does the surgeon primarily use (saline, silicone, *Responsive* silicone, *SoftTouch* silicone, *Highly Cohesive* silicone)?
- Has he/she completed Allergan's Physician Certification Program for the use of its silicone-filled breast implants?

- Is he/she board certified, and, if so, with which board?
- Did he/she complete a residency in plastic surgery from a recognized and accredited program?
- In which state(s) is he/she licensed to practice surgery? (Note that some states provide information on disciplinary action and malpractice claims/settlements to prospective patients, either by request or on the Internet.)
- What is the most common complication he/she encounters with breast augmentation?
- What is his/her reoperation rate with breast augmentation, and what is the most common type of reoperation he/she performs?
- Can he/she perform this surgery in a hospital, as well as in the surgeon's independent surgery center? (Note that hospitals require evidence of appropriate training in specific procedures before allowing surgeons to operate in their facilities.)

The following list of questions may help to remind you of topics to discuss with your surgeon. You may have other questions as well.

- What are the risks and complications associated with having breast implants?
- How many additional operations on my implanted breast(s) can I expect over my lifetime?
- How will my breasts look if I decide to have the implants removed without replacement?
- What shape, size, surface texturing, incision site, and placement site is recommended for me?
- How will my ability to breastfeed be affected?
- How can I expect my implanted breasts to look over time?
- How can I expect my implanted breasts to look after pregnancy? After breastfeeding?
- What are my options if I am dissatisfied with the cosmetic outcome of my implanted breasts?
- What alternate procedures or products are available if I choose not to have breast implants?
- Do you have before and after photos I can look at for each procedure and what results are reasonable for me?

3.3 What Are Choices and Options Associated with the Surgery?

There are 2 approved types of breast implant fillers (saline and silicone), and Allergan has 3 types of silicone fillers (*Responsive* silicone gel, *SoftTouch* silicone gel, and *Highly Cohesive* silicone gel). These options allow your surgeon to use the best type of implant to achieve the effect you desire. Your surgeon can discuss these options with you and may make recommendations to you based upon the physical contours of your body. This document is for *Responsive*, *SoftTouch*, and *Highly Cohesive* silicone-filled round breast implants; a separate document is available for saline-filled breast implants. Carefully review the section on risks and the section on Allergan's clinical study so that you may make an informed choice. Be sure to ask your surgeon to see and touch samples of *Responsive*, *SoftTouch*, and *Highly Cohesive* silicone-filled breast implants as well as saline-filled breast implants.

The **NATRELLE**[®] Collection

The **NATRELLE**[®] Collection includes both saline-filled and silicone gel-filled implants, allowing you and your surgeon to select the best implant for your needs.

NATRELLE[®] Saline-Filled Breast Implants

NATRELLE[®] Saline-Filled Breast Implants have a self-sealing valve that is used for filling the implant with sterile saline solution (saltwater) at the time of surgery. Saline solutions are very common and are used to clean wounds and the surface of the eye. The watery saline solution used in breast implants is isotonic (has the same salt concentration as the normal cells of the body and the blood) and presents no health risk to the patient even if the implant deflates and the saline leaks out. **NATRELLE**[®] Saline-Filled Breast Implants typically require a smaller incision. However, visible wrinkling or rippling of the skin over the implant may be more likely to occur.

NATRELLE[®] Silicone-Filled Breast Implants

NATRELLE[®] Silicone-Filled Breast Implants are pre-filled with a soft cohesive silicone gel, which may make the implant feel more "natural." Other medical devices utilizing silicones are artificial joints, catheters, drainage systems, facial implants, and tissue expanders. The silicone gel used in **NATRELLE**[®] Silicone-Filled Breast Implants has been shown to be **biocompatible**, making it an appropriate choice for breast implants. Silicone-filled breast implants typically require a larger incision than used for saline implants; however, they may look and feel more natural.

Implant Gel Fill, Shape, and Size

NATRELLE[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®]

Breast Implants are round implants that come in a variety of profiles and sizes. **NATRELLE**[®] Silicone-Filled Breast Implants are filled with *Responsive* gel. **NATRELLE INSPIRA**[®] Breast Implants are filled with *Responsive* gel, *SoftTouch* gel, or *Highly Cohesive* gel. Each gel filling varies in the amount of firmness it provides to the implant. Responsive silicone gel is the least firm gel and Highly Cohesive is the most firm gel offered. SoftTouch silicone gel has a firmness level that is in between that of the Responsive silicone gel and the Highly Cohesive silicone gel. In general, **NATRELLE INSPIRA**[®] Breast Implants have a fuller appearance than **NATRELLE**[®] Silicone-Filled Breast Implants. Your plastic surgeon will discuss with you the implant options that will best help you achieve the result that is right for you.

The following figures and tables may help you to understand the various sizes and styles of implants as your surgeon discusses the various options with you. Depending on the desired shape you wish to achieve, you and your surgeon have implants with different round profiles, or styles, and sizes from which to choose. Generally, the larger you want your cup size, the larger the breast implant size or the higher the profile the surgeon will consider. Breast implant sizes are measured in volume, by cubic centimeters (cc), not in cup sizes, because cup size depends on the size and shape of the individual woman's chest. Overviews of the styles and sizes of **NATRELLE**[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®] Breast Implants are provided in the tables below.

Approved **NATRELLE**[®] Silicone-Filled Breast Implant Styles

Style Number	Breast Implant Description	Size Range
Style 10	Smooth shell surface, <i>Responsive</i> silicone gel, moderate profile	120cc – 800cc
Style 15	Smooth shell surface, <i>Responsive</i> silicone gel, moderate-plus profile	155cc – 752cc
Style 20	Smooth shell surface, <i>Responsive</i> silicone gel, high profile	120cc – 800cc
Style 40	Smooth shell surface, <i>Responsive</i> silicone gel, moderate profile	80cc – 560cc
Style 45	Smooth shell surface, <i>Responsive</i> silicone gel, extra-high profile	120cc – 800cc



Natrelle[®] Style 10
Moderate Profile



Natrelle[®] Style 15
Moderate-Plus Profile



Natrelle[®] Style 20
High Profile



Natrelle[®] Style 45
Extra-High Profile

Approved NATRELLE INSPIRA® Responsive Breast Implant Styles

Style Name	Breast Implant Description	Size Range
Style SRL	Smooth shell surface, <i>Responsive</i> silicone gel, low profile	110cc – 610cc
Style SRLP	Smooth shell surface, <i>Responsive</i> silicone gel, low plus profile	125cc – 640cc
Style SRM	Smooth shell surface, <i>Responsive</i> silicone gel, moderate profile	140cc – 755cc
Style SRF	Smooth shell surface, <i>Responsive</i> silicone gel, full profile	180cc – 770cc
Style SRX	Smooth shell surface, <i>Responsive</i> silicone gel, extra-full profile	200cc – 800cc

Approved NATRELLE INSPIRA® SoftTouch Breast Implant Styles

Style Name	Breast Implant Description	Size Range
Style SSL	Smooth shell surface, <i>SoftTouch</i> silicone gel, low profile	110cc – 610cc
Style SSLP	Smooth shell surface, <i>SoftTouch</i> silicone gel, low plus profile	125cc – 640cc
Style SSM	Smooth shell surface, <i>SoftTouch</i> silicone gel, moderate profile	140cc – 755cc
Style SSF	Smooth shell surface, <i>SoftTouch</i> silicone gel, full profile	180cc – 770cc
Style SSX	Smooth shell surface, <i>SoftTouch</i> silicone gel, extra-full profile	200cc – 800cc

Approved NATRELLE INSPIRA® Cohesive Breast Implant Styles

Style Name	Breast Implant Description	Size Range
Style SCL	Smooth shell surface, <i>Highly Cohesive</i> silicone gel, low profile	110cc – 610cc
Style SCLP	Smooth shell surface <i>Highly Cohesive</i> silicone gel, low plus profile	125cc – 640cc
Style SCM	Smooth shell surface <i>Highly Cohesive</i> silicone gel, moderate profile	140cc – 755cc
Style SCF	Smooth shell surface, <i>Highly Cohesive</i> silicone gel, full profile	180cc – 770cc
Style SCX	Smooth shell surface, <i>Highly Cohesive</i> silicone gel, extra-full profile	200cc – 800cc




Your surgeon will also evaluate your existing breast and skin tissue to determine if you have enough tissue to cover the breast implant you are considering. In some cases, such as after pregnancy, you might have too much extra skin. If you desire a breast implant size that is too large for your tissue, the surgeon may warn you that breast implant edges may be visible or palpable postoperatively. Also, excessively large breast implants may speed up the effects of gravity on the breast and can make your breasts droop or sag at an earlier age. Larger sized implants may be too large for many women, and can increase the risk of implant extrusion, hematoma, infection, palpable implant folds, or visible skin wrinkling. In Allergan’s Core Study, a risk factor analysis showed a trend in one cohort towards an increased risk of capsular contracture with larger size implants. However, this relationship was not consistent across cohorts and timepoints, and the capsular contracture rate remained low for all cohorts.

Surface


NATRELLE® Silicone-Filled Breast Implants and **NATRELLE INSPIRA®** Breast Implants come in a variety of profiles and sizes with a smooth surface shell. Some studies suggest that surface texturing reduces the chance of severe capsular contracture,¹⁴ while other studies do not.^{12,13} Allergan's Core Study did not show a difference in the likelihood of developing capsular contracture with textured implants compared to smooth implants.

Implant Placement

The breast implant can be placed either partially under the pectoralis major muscle (submuscular) or on top of the muscle and under the breast glands (subglandular). You should discuss with your surgeon the advantages and disadvantages of each implant placement. Several of these advantages and disadvantages are described in the table below.



Breast before augmentation



Breast after subglandular augmentation



Breast after submuscular augmentation


Comparison between Subglandular versus Submuscular Placement

Subglandular Placement	Submuscular Placement
Surgery may be shorter	Surgery may be longer
Recovery may be shorter	Recovery may be longer
May be less painful	May be more painful
May provide easier access for reoperation	Reoperation may be more difficult
More visible and palpable implants	Less visible and palpable implants
Greater likelihood of capsular contracture ^{12,13}	Less likelihood of capsular contracture ¹⁴
More difficult imaging during mammography exam	Easier imaging during mammography exam
May not be recommended if you have thin or weakened breast tissue.	May be preferable if you have thin or weakened breast tissue

Incision Sites

You should discuss with your surgeon the pros and cons for the incision site specifically recommended for you.

Breast augmentation with *Responsive* silicone implants requires a larger incision size than saline implants, and augmentation with *SoftTouch* or *Highly Cohesive* silicone implants requires a larger incision size than *Responsive* implants. There are 3 common incision sites: around the nipple (periareolar), within the breast fold (inframammary), or under the arm (axillary or transaxillary).



- **Periareolar** - This incision is typically more concealed, but since it also involves cutting through the breast tissue, it is associated with a higher likelihood of breastfeeding difficulties, as compared to the other incision sites. Cutting through the tissue may make a change in sensation or infection more of a concern.
- **Inframammary** - This incision is generally less concealed than periareolar but it is associated with fewer breastfeeding difficulties than the periareolar incision site. It is also the most commonly used incision site at the present time because many surgeons feel it gives the best access to and control of the breast implant pocket.
- **Transaxillary** - This incision is less concealed than periareolar and associated with fewer breastfeeding difficulties than the periareolar incision site. If the incision is made under the arm, the surgeon may use a probe fitted with a miniature camera, along with very small instruments, to create a “pocket” for the breast implant. This approach is more difficult, and may increase the risk of damage to, and unexpected location of, the implant.
- **Umbilical (belly button)** - This incision site has not been studied in Allergan’s Core Study and should not be used for a wide variety of reasons, including potential damage to the implant shell.

Additional Procedures at the Time of Breast Augmentation

Your surgeon will examine your breasts and help you make decisions to obtain the best result in your individual situation. In some cases, implants alone may not address all of the issues, such as sagging or extra skin, affecting your breasts. This is particularly true if there is extra skin remaining from when the breasts were engorged with milk, or if you have lost a significant amount of weight.

In these situations, your surgeon may recommend a breast lift (mastopexy) to remove some of the extra skin, or to lift the breasts, at the time of implant placement. Mastopexy involves removing a strip of skin from under the breast or around the nipple to lift the nipple and breast

location, and tighten the skin over the breast. Your surgeon will discuss the potential risks, and the location of the additional scars which might be required to lift your breasts or to remove the extra skin.

Implant Palpability

Implants may be more palpable or noticeable if there is an insufficient amount of skin/tissue available to cover the implant and/or when the implant is placed underneath and within the breast glands (breast tissue) but on top of the chest muscle.

Surgical Setting and Anesthesia

Augmentation surgery is usually performed on an outpatient basis, in a specialized operating room which may be located in a hospital, a surgery center, or surgical suite in the surgeon's office. General anesthesia is commonly used, and local anesthesia with sedation is also an option. You should be sure to check with your surgeon and with the facility where the surgery will take place, to become aware of the tests, presurgical examinations, and length of time you need to be without food or your routine medications prior to the surgical procedure.

Postoperative Care

You will probably feel somewhat tired and sore for several days following the operation, and your breasts may remain swollen and sensitive to physical contact for a month or longer. You may also experience a feeling of tightness in the breast area as your skin adjusts to your new breast size. The breasts and nipple area also may have less feeling during this time of swelling and immediately after surgery. Other possible complications have been described above.

Postoperative care depends on each patient's situation and may involve using a special postoperative bra, compression bandage, or jog bra for extra support and positioning while you heal. Some surgeons may not want you to wear a bra at all for a period of time following the surgery.

Your surgeon may place postoperative pain balls or other pain medication infusion devices alongside the breast implant to help control your pain after surgery.

At your surgeon's recommendation, you will most likely be able to return to work within a few days. However, for at least a couple of weeks you should avoid any strenuous activities that could raise your pulse and blood pressure or require strenuous use of your arms and chest.

Note: If you experience fever, do not feel well, or see noticeable swelling, redness or drainage in your implanted breast(s), you should contact your surgeon immediately.

Other Factors to Consider In Revision-Augmentation Surgery

Some revision surgeries require removal of an intact implant (for example, capsulotomy and pocket adjustments), while others leave the implant in place. Any device that has been removed during revision surgery should not be re-implanted. Allergan breast implants are "for single use only."

4.0 FOLLOW-UP EXAMINATIONS

After your breast implant surgery, you will need regular examinations to detect potential complications. You should inform any doctor who treats you of the presence of your implants to minimize the risk of damage to the implants.

Breast Self-Examinations

Following breast augmentation, you should continue to perform a breast self-examination monthly. This may be more difficult with a breast implant in place. To continue to perform a monthly breast self-examination efficiently, you should ask your surgeon to help you identify the difference between the implant and your breast tissue. Being able to identify the implant from breast tissue will decrease the necessity of excessive squeezing of the implant during examination. If you have pain in your breasts, or you find any lumps, swelling, hardening, or change in implant shape, you should report these to your surgeon. In some cases, your surgeon may recommend an MRI or ultrasound to screen for breast implant rupture. Any new lumps should be evaluated with a biopsy, as appropriate. If a biopsy is performed, be sure to inform the medical professional performing the biopsy that you have breast implants so that care will be taken to avoid injuring the implant.

Screening for Silent Rupture

Because most ruptures of silicone-filled breast implants are silent, in most cases neither you nor your surgeon will be able to find evidence of rupture by a physical examination. Therefore, a different method is needed to screen for implant rupture. Even if you have no symptoms, you should have your first ultrasound or MRI at 5-6 years after your initial implant surgery and then every 2-3 years thereafter. If you have symptoms at any time or uncertain ultrasound results for breast implant rupture, an MRI is recommended. The MRI should be performed at a center with a breast coil utilizing a magnet of at least 1.5 Tesla and read by a radiologist who is familiar with looking for implant rupture. Your doctor should assist you in locating a radiology/screening center, as well as a radiologist who is familiar with the MRI techniques and equipment used to screen breast implants for silent rupture. If there are signs of rupture on imaging, you should have your implant removed or replaced. More information on rupture is provided in [Section 2.3](#) of this document.

Symptomatic Rupture

Symptoms associated with rupture may include hard knots or lumps surrounding the implant or in the armpit, loss of size of the breast or implant, pain, tingling, swelling, numbness, burning, or hardening of the breast. If you notice any of these changes, see your plastic surgeon. He or she will examine the implants and determine whether you need to have an MRI examination to find out if your implant has ruptured. As a precaution, Allergan recommends that ruptured implants be taken out and either replaced with a new implant or not replaced, depending on your preference or medical need. Consult with your doctor regarding this and any other medical decisions related to your implants.

Mammography

The current recommendations for getting screening/preoperative mammograms are no different for women with breast implants than for those without implants. You need to tell your mammography technologist before the procedure that you have an implant.

Mammography exams should be interpreted by radiologists experienced in the evaluation of women with breast implants. Your surgeon should request a diagnostic mammogram, rather than a screening mammogram, because more pictures are taken with diagnostic mammography. The technologist can use special techniques to reduce the possibility of rupture and to get the best possible views of the breast tissue.

5.0 ALLERGAN'S CLINICAL STUDY RESULTS

This section of the document summarizes the results of the Allergan Core Study conducted on **NATRELLE**[®] Silicone-Filled Breast Implants for Primary Augmentation and Revision-Augmentation. The Allergan Core Study was the primary clinical study for this product. The Allergan Core Study included both smooth and BIOCELL textured breast implants. The BIOCELL textured breast implants were recalled in July 2019 for their higher risk associated with BIA-ALCL and no longer are manufactured or marketed. The results of the Core Study give you useful information on the experience of other women with **NATRELLE**[®] Silicone-Filled Breast Implants. While the results cannot be used to predict your individual outcome, they can be used as a general guide to what you may expect. Your own complications and benefits depend on many individual factors.

As a note, supplemental safety information was also obtained from another Allergan clinical study (the Adjunct Study), the Danish Breast Implant Registry, an international clinical MRI study, and the literature to help assess long-term rupture rate and the consequences of rupture for this product. The literature, which had the most available information on the consequences of rupture, was also used to assess other potential complications associated with silicone gel-filled breast implants. The key literature information was discussed throughout the [Breast Implant Risks](#) section above, and the references can be found at the end of this document.

5.1 What Are the Overview Findings of Allergan's Core Study?

The Allergan Core Study was a 10-year study to assess safety and effectiveness in Primary Augmentation, Primary Reconstruction, and Revision (Revision-Augmentation and Revision-Reconstruction) patients. Patient follow-up was at 0-4 weeks, 6 months, 12 months, and annually through 10 years. Safety was assessed by complications, such as implant rupture, capsular contracture, and reoperation. Benefit (effectiveness) was assessed by breast size change, patient satisfaction, and measures of quality of life.

The Allergan Core Study consisted of 715 patients. This included 455 Primary Augmentation patients, 147 Revision-Augmentation patients, 98 Primary Reconstruction patients, and 15 Revision-Reconstruction patients. Of these patients, 158 Primary Augmentation patients, 50 Revision-Augmentation patients, 51 Primary Reconstruction patients, and 5 Revision-Reconstruction patients were in the MRI cohort, which means that they were assessed for silent rupture by MRI at years 1, 3, 5, 7, and 9. Final results through 10 years are reported in this document.

Allergan's Core Study results indicated that 49% for Primary Augmentation patients and 64% for Revision-Augmentation patients will have at least 1 occurrence of any complication (including reoperation) at some point through 10 years after implant surgery. The information below provides more details about the complications and benefits you may experience. More detailed data tables are found in the Appendix of this document. Please refer to the glossary for the definition of any complication you may not understand.

5.2 What Are the 10-Year Follow-Up Rates?

Follow-up rates from a clinical study show you how many women continue to provide information on their experience with breast implants.

The Allergan Core Study enrolled 455 Primary Augmentation patients. Of the women expected to be seen at the 10-year follow-up visit, 67% were seen.


The Allergan Core Study enrolled 147 Revision-Augmentation patients. Of the women expected to be seen at the 10-year follow-up visit, 64% were seen.

5.3 What Are the Benefits?

The benefits of **NATRELLE**[®] Silicone-Filled Breast Implants were assessed by a variety of outcomes, including bra cup size change and assessments of patient satisfaction and quality of life. Data were collected before implantation and at scheduled follow-up visits through 10 years.

Breast Measurement: For Primary Augmentation patients, 396 (87%) of the original 455 patients had a breast measurement within 18 months of surgery. Of these 396 patients, 41% increased by 1 cup size; 45% increased by 2 cup sizes; 8% increased by more than 2 cup sizes; and 5% had no increase. See Figure 1 below.


Revision-Augmentation patients did not undergo a measurement of breast cup size change because they were undergoing replacement of an existing breast implant.



Patient Satisfaction: Patients used a 5-point scale to rate their level of satisfaction with their implants at the time of the follow-up visits. Of the original 455 Primary Augmentation patients, 279 (61%) provided a satisfaction rating at 10 years after implantation. Of these 279 patients, 86% indicated that they were definitely satisfied with their breast implants, 8% indicated they were somewhat satisfied, 2% indicated that they were neither satisfied nor dissatisfied, 2% were indicated they were somewhat dissatisfied, and 2% indicated they were definitely dissatisfied.

Of the original 147 Revision-Augmentation patients, 74 (50%) provided a satisfaction rating at 10 years. Of these 74 patients, 73% indicated they were definitely satisfied with their breast implants, 11% indicated that they were somewhat satisfied, 3% indicated that they were neither satisfied nor dissatisfied, 7% indicated they were somewhat dissatisfied, and 7% indicated that they were definitely dissatisfied. See Figure 2 below, which indicates the percentage of patients who were satisfied or very satisfied with their breast implants through 10 years.

Figure 2. Primary Augmentation and Revision-Augmentation Patient Satisfaction Through 10 Years (responses of somewhat satisfied, satisfied, or definitely satisfied)



Quality of Life Assessments: To assess quality of life, Primary Augmentation patients answered a series of questions collected from several quality of life scales.

For Primary Augmentation patients, scores on the SF-36, which measure mental and physical health, showed an improvement in 1 scale (Reported Health Transition) and a worsening in 6 scales (Role Emotional Problems, Role Physical Health Problems, General Health, Social Functioning, Vitality, and Mental Health) after 10 years compared to before breast implantation, although all scales remained higher than the general U.S. female population. Rosenberg Self-Esteem Scale generally showed no significant changes at 10 years, and scores on the Body Esteem Scale generally showed decreases in weight concern and physical condition and an increase with regard to sexual attractiveness. Scores on the Rowland Expectation instrument showed significant improvement in "self image," "social relations," and "daily living" at 10 years.

Primary Augmentation patients also had significantly improved satisfaction with specific aspects of their breasts after 10 years, including satisfaction with breast size, shape, feel, and how well they matched.

For Revision-Augmentation patients, scores on the SF-36 showed no significant changes in all of the scales but one (Vitality), which showed a decrease after 10 years, although all scales remained higher than the general U.S. female population. Scores on the Rosenberg Self-Esteem scale showed no significant changes at 10 years. Scores on the Body Esteem Scale showed no significant changes in all of the scales but one,

which showed a decrease in physical condition at 10 years. Scores on the Rowland Expectation instrument showed significant improvement in “self-image,” “social relations,” and “daily living” at 10 years.

Revision-Augmentation patients also had significantly improved satisfaction with specific aspects of their breasts after 10 years, including satisfaction with breast size, shape, feel, and how well they matched.

5.4 What Are the 10-Year Complication Rates?

The complications observed in Primary Augmentation and Revision-Augmentation women are presented in Table 2 and Table 3, respectively. The rates reflect the percentage of patients who experienced the listed complication at least once within the first 3, 5, 7, or 10 years after their implant surgery. Some complications occurred more than once for some patients. Please refer to the Glossary at the front of this document for the definition of any complication you may not understand.

The most common complications for Primary Augmentation patients within the first 10 years following implantation were reoperation (36% or approximately 36 patients out of 100) and capsular contracture (19% or 19 patients out of 100). The most common complications Revision-Augmentation patients experienced were reoperation (46%) and implant removal with replacement (35%).

Table 2
Complication Rates for
Primary Augmentation Patients (N = 455)

Key Complications ^a		Year 3	Year 5	Year 7	Year 10
Reoperation		19.9%	25.5%	30.2%	36.1%
Implant Rupture	MRI Cohort	2.0%	5.0%	7.4%	9.3%
	Non-MRI Cohort	2.2%	10.5%	11.1%	13.7%
Implant Replacement		6.1%	9.3%	11.1%	18.6%
Capsular Contracture (Baker Grade III/IV)		10.7%	13.0%	16.2%	18.9%
Implant Removal without Replacement		0.7%	2.3%	2.8%	2.8%
Other Complications Occurring in at least 1% of Patients ^{b,c}		Year 3	Year 5	Year 7	Year 10
Asymmetry		2.7 %	2.7%	3.0%	3.3%
Breast Pain		8.3%	8.8%	10.5%	11.5%
Breast/Skin Sensation Changes		1.6%	1.6%	1.6%	1.6%
Delayed Wound Healing		1.1%	1.1%	1.1%	1.1%
Hematoma		1.6%	1.6%	1.6%	1.6%
Hypertrophic/Other Abnormal Scarring		3.7%	4.2%	4.2%	4.2%
Implant Malposition		5.4%	5.9%	5.9%	6.9%

Key Complications ^a	Year 3	Year 5	Year 7	Year 10
Implant Palpability/visibility	1.4%	1.6%	1.6%	1.6%
Nipple Complications	5.1%	5.7%	6.0%	6.3%
Ptosis	0.9%	1.7%	2.0%	2.0%
Seroma	1.8%	1.8%	1.8%	1.8%
Swelling	7.8%	7.8%	8.9%	9.2%
Wrinkling/Rippling	0.9%	1.5%	1.5%	1.8%
Other Complications ^d	0.2%	0.2%	0.2%	0.2%

a Most complications were assessed with severity ratings. This table only includes complications rated moderate, severe, or very severe (excludes mild and very mild ratings). For reoperation, implant removal or replacement, implant rupture, implant extrusion, and pneumothorax all occurrences are included.

b The following complications occurred at a rate less than 1.0% at all timepoints: bruising, gel migration, implant extrusion, infection, lymphedema, redness, skin rash, tissue necrosis

c The following complications were reported at a rate of 0%: capsule calcification, irritation, lymphadenopathy, pneumothorax

d Other complications include flexion of pectoral (chest) muscles creating a deforming band in a slanted manner (obliquely) beneath the nipple.

Table 3
Complication Rates for
Revision-Augmentation Patients (N = 147)

Key Complications ^a		Year 3	Year 5	Year 7	Year 10
Reoperation		32.4%	36.8%	40.7%	46.0%
Implant Rupture	MRI Cohort	0%	0%	0%	5.4%
	Non-MRI Cohort	1.8%	3.9%	3.9%	10.1%
Implant Replacement		10.1%	16.1%	21.8%	30.1%
Capsular Contracture (Baker Grade III/IV)		16.8%	18.4%	20.2%	28.7%
Implant Removal without Replacement		2.3%	3.1%	4.0%	4.0%
Other Complications Occurring in at least 1% of Patients^{b,c}		Year 3	Year 5	Year 7	Year 10
Asymmetry		2.8%	5.3%	5.3%	6.5%
Breast Pain		7.6%	8.5%	10.5%	11.7%
Breast/Skin Sensation Changes		1.4%	2.2%	2.2%	2.2%
Bruising		2.1%	2.1%	3.0%	3.0%
Hematoma		2.1%	2.1%	2.1%	2.1%
Hypertrophic/Other Abnormal Scarring		5.8%	6.6%	6.6%	6.6%
Implant Malposition		4.4%	6.0%	6.0%	6.0%
Implant Palpability/Visibility		4.3%	6.0%	6.0%	6.0%
Infection		1.4%	1.4%	1.4%	1.4%
Nipple Complications		1.4%	1.4%	1.4%	1.4%

Key Complications ^a	Year 3	Year 5	Year 7	Year 10
Ptosis	1.5%	4.0%	4.9%	4.9%
Seroma	5.0%	5.0%	6.0%	6.0%
Swelling	6.3%	7.2%	8.2%	8.2%
Wrinkling/Rippling	4.6%	5.4%	5.4%	5.4%
Other Complications ^d	0.7%	0.7%	0.7%	0.7%

a Most complications were assessed with severity ratings. This table only includes complications rated moderate, severe, or very severe (excludes mild and very mild ratings). For reoperation, implant removal or replacement, implant rupture, implant extrusion, and pneumothorax all occurrences are included.

b The following complications occurred at a rate less than 1.0% at all timepoints: delayed wound healing, irritation, redness, skin rash

c The following complications were reported at a rate of 0%: capsule calcification, gel migration, implant extrusion, lymphadenopathy, lymphedema, pneumothorax, tissue/skin necrosis

d Other complications include herniation (abnormal protrusion of tissue through an opening) following an auto accident

5.5 What Are the Main Reasons for Reoperation?

The reasons Primary Augmentation and Revision-Augmentation patients underwent additional surgery for their breast implant (reoperation) at years 3, 5, 7, and 10 are presented in Table 4 and Table 5, respectively.

Women may have had a reoperation for one or more reasons.

Furthermore, a surgeon may perform multiple surgical procedures during a single reoperation. For example, during a single reoperation a surgeon may perform incision and drainage, remove the capsule, replace the implant, reposition the implant, and perform scar revision.

In Allergan's Core Study through 10 years, there were 581 surgical procedures performed during 221 reoperations involving 153 Primary Augmentation patients. The most common reason for reoperation through 10 years in Primary Augmentation patients was because of capsular contracture (55 of 221 reoperations).

In Allergan's Core Study through 10 years, there were 317 surgical procedures performed during 108 reoperations involving 63 Revision-Augmentation patients. The most common reason for reoperation through 10 years in Revision-Augmentation patients was also because of capsular contracture (26 of 108 reoperations).

Table 4
Main Reasons for Reoperation for Primary Augmentation Patients

Main Reason for Reoperation	Year 3	Year 5	Year 7	Year 10
Asymmetry	4 (3.5%)	5 (3.3%)	5 (2.8%)	5 (2.3%)
Biopsy	11 (9.6%)	13 (8.5%)	22 (12.2%)	28 (12.7%)
Breast Mass/Cyst/Lump	1 (0.9%)	1 (0.7%)	3 (1.7%)	4 (1.8%)
Breast pain	1 (0.9%)	2 (1.3%)	3 (1.7%)	3 (1.4%)
Capsular contracture	37 (32.2%)	43 (28.1%)	48 (26.7%)	55 (24.9%)
Delayed wound healing	3 (2.6%)	3 (2.0%)	3 (1.7%)	3 (1.4%)
Hematoma/seroma	9 (7.8%)	10 (6.5%)	12 (6.7%)	13 (5.9%)
Implant extrusion	1 (0.9%)	1 (0.7%)	1 (0.6%)	1 (0.5%)
Implant malposition	18 (15.7%)	24 (15.7%)	26 (14.4%)	27 (12.2%)
Implant palpability	0	1 (0.7%)	1 (0.6%)	1 (0.5%)
Implant rupture (suspected)	1 (0.9%)	7 (4.6%)	12 (6.7%)	29 (13.1%)
Infection	0	2 (1.3%)	2 (1.1%)	2 (0.9%)
Necrosis	1 (0.9%)	1 (0.7%)	1 (0.6%)	1 (0.5%)
Nipple complications (unplanned)	1 (0.9%)	1 (0.7%)	1 (0.6%)	1 (0.5%)
Patient request for style/size change	5 (4.3%)	9 (5.9%)	9 (5.0%)	12 (5.4%)
Ptosis	16 (13.9%)	20 (13.1%)	21 (11.7%)	25 (11.3%)
Scarring/hypertrophic scarring	5 (4.3%)	8 (5.2%)	8 (4.4%)	8 (3.6%)
Wrinkling/rippling	1 (0.9%)	2 (1.3%)	2 (1.1%)	3 (1.4%)
Total	115 Reoperations (100%)	153 Reoperations (100%)	180 Reoperations (100%)	221 Reoperations (100%)

Table 5
Main Reasons for Reoperation for Revision-Augmentation Patients

Main Reason for Reoperation	Year 3	Year 5	Year 7	Year 10
Asymmetry	3 (4.1%)	3 (3.3%)	3 (3.1%)	3 (2.8%)
Biopsy	6 (8.1%)	8 (8.9%)	8 (8.2%)	9 (8.3%)
Breast Cancer mass	1 (1.4%)	2 (2.2%)	3 (3.1%)	3 (2.8%)
Breast pain	1 (1.4%)	1 (1.1%)	1 (1.0%)	1 (0.9%)
Breast tissue contour deformity	1 (1.4%)	1 (1.1%)	1 (1.0%)	1 (0.9%)
Capsular contracture	12 (16.2%)	17 (18.9%)	20 (20.4%)	26 (24.1%)
Delayed wound healing	2 (2.7%)	2 (2.2%)	2 (2.0%)	2 (1.9%)
Device Injury – Iatrogenic or Traumatic	1 (1.4%)	1 (1.1%)	1 (1.0%)	1 (0.9%)
Hematoma/seroma	12 (16.2%)	13 (14.4%)	13 (13.3%)	13 (12.0%)
Implant extrusion	1 (1.4%)	1 (1.1%)	1 (1.0%)	1 (0.9%)
Implant malposition	8 (10.8%)	11 (12.2%)	11 (11.2%)	12 (11.1%)
Implant palpability/visibility	1 (1.4%)	1 (1.1%)	1 (1.0%)	1 (0.9%)
Implant rupture (suspected)	4 (5.4%)	4 (4.4%)	5 (5.1%)	7 (6.5%)
Infection	2 (2.7%)	2 (2.2%)	3 (3.1%)	3 (2.8%)
Nipple Complications (unplanned)	3 (4.1%)	3 (3.3%)	3 (3.1%)	3 (2.8%)
Patient request for style/size change	3 (4.1%)	3 (3.3%)	3 (3.1%)	3 (2.8%)
Ptosis	5 (6.8%)	8 (8.9%)	9 (9.2%)	9 (8.3%)
Scarring/hypertrophic scarring	6 (8.1%)	7 (7.8%)	7 (7.1%)	7 (6.5%)
Wrinkling/rippling	1 (1.4%)	1 (1.1%)	2 (2.0%)	2 (1.9%)
Unknown	1 (1.4%)	1 (1.1%)	1 (1.0%)	1 (0.9%)
Total	74 Reoperations (100%)	90 Reoperations (100%)	98 Reoperations (100%)	108 Reoperations (100%)

5.6 What Are the Main Reasons for Implant Removal?

The main reasons Primary Augmentation and Revision-Augmentation patients had implants removed through 10 years are presented in Figures 3 and 4, respectively. For Primary Augmentation, 156 implants were removed from 84 patients. Of these 156 implants, 135 were replaced. The most common reason for implant removal was capsular contracture (50 of the 156 implants removed).

For Revision-Augmentation, 78 implants were removed from 42 patients. Of these 78 implants, 71 were replaced. The most common reason for implant removal was also due to capsular contracture (28 of the 78 implants removed).

Figure 3. Main Reasons for Implant Removal Through 10 Years Primary Augmentation (N = 156 implants)





Figure 4. Main Reasons for Implant Removal Through 10 Years Revision Augmentation (N = 78 implants)



5.7 What Are Other Clinical Data Findings?

Below is a summary of clinical findings from the Allergan Core Study with regard to connective tissue disease (CTD), CTD signs and symptoms, cancer, lactation complications, reproduction complications, and suicide. These issues, along with others, are being further evaluated as part of an Allergan post-approval study of a large number of patients followed through 10 years (Breast Implant Follow-Up Study, or BIFS).

Implant Rupture

The rupture rate for the whole MRI cohort in the Core Study (including Augmentation, Revision-Augmentation, Reconstruction, and Revision-Reconstruction patients) through 10 years was 13.0% for patients and 7.7% for implants. For the non-MRI cohort the rupture rate through 10 years was 9.5% for patients and 5.6% for implants. For Primary Augmentation patients in the MRI cohort, 9.3% of patients had a ruptured implant and 5.5% of implants ruptured through 10 years. For Revision-Augmentation patients in the MRI cohort, 5.4% of patients had a ruptured implant and 2.9% of implants ruptured through 10 years. This means that through 10 years, approximately 9 out of every 100 Primary Augmentation patients and 5 out of every 100 Revision-Augmentation patients had at least one ruptured breast implant.

Across all patients in the Core Study, all ruptures were intracapsular with 3 cases of both intracapsular and extracapsular gel (one rupture progressed to extracapsular gel following exploratory surgery to confirm the rupture and then implant replacement was delayed).

CTD Diagnoses

Five Primary Augmentation patients (1.1%) reported new diagnoses of CTD: 2 with rheumatoid arthritis at 7 months and at 3 years after implantation, 2 patients with fibromyalgia at 3 years and 4.5 years after implantation, and 1 patient with Raynaud Syndrome 5 years after implantation. Two Revision-Augmentation patients (1.4%) were reported new diagnoses of CTD: 1 with fibromyalgia at 10 months after implantation and 1 with rheumatoid arthritis nearly 8 years after implantation. It cannot be concluded that these CTD diagnoses were caused by the implant because there was no comparison group of similar women without implants.

CTD Signs and Symptoms

Patients who are not diagnosed with a CTD may still have some of the signs or symptoms of these diseases. In Allergan's Core Study, self-reported signs and symptoms were collected at the 2, 4, 6, 8, and 10-year follow-up visits in the categories of General, Gastrointestinal, Neurological, Urinary, Global, Pain, Fatigue, Fibromyalgia, Joint, Muscular, Skin, and Other. For Primary Augmentation patients at 10 years after implantation, statistically significant increases after accounting for age were found for the

symptom categories of Skin, Urinary, and Other. For Revision-Augmentation patients at 10 years after implantation, no statistically significant changes in any of the symptoms categories were found.

The Core Study was not designed to evaluate cause-and-effect associations because there is no comparison group of women without implants. Furthermore, other factors that might contribute to CTD signs and symptoms such as medications, lifestyle and exercise, were not studied. Therefore, it cannot be determined whether any increase in CTD signs and symptoms was due to the implants or not, based on the Core Study. However, you should be aware that you may experience an increase in these symptoms after receiving breast implants.

Cancer

There were 4 Primary Augmentation patients with a new diagnosis of breast cancer through 10 years in the Allergan Core Study. In Primary Augmentation patients there was 1 report of thyroid cancer and 1 report of brain cancer.

For Revision-Augmentation patients, there was 1 patient with a new diagnosis of breast cancer. There were no reports of other cancers, such as respiratory or cervical/vulvar, in Revision-Augmentation patients.

No patients in the Core Study were reported with ALCL through 10 years.

Lactation Complications

Eighteen (23%) of the 78 Primary Augmentation patients who attempted to breastfeed following breast implantation in the Core Study through 10 years reported difficulty with breastfeeding. The most common difficulty was inadequate milk production. For the 20 Revision-Augmentation patients who attempted to breastfeed after receiving breast implants, 6 (30%) had difficulty breastfeeding, 5 due to inadequate milk production and 1 due to pain.

Reproduction Complications

Thirty-six (8%) of the Primary Augmentation patients in the Allergan Core Study reported a reproduction problem through 10 years, most commonly miscarriage. For the 6 Revision-Augmentation patients (4%) who experienced a reproduction problem through 10 years, the most common problem was miscarriage.

Suicide

There was 1 report of suicide in Primary Augmentation patients and 2 reports of suicide in Revision-Augmentation patients in the Allergan Core Study through 10 years.

6.0 ADDITIONAL INFORMATION

6.1 What If I Experience a Problem?

Device Identification Card

You will be given a device identification card with the style and serial number of your breast implant(s). This card is for your permanent record and should be kept in a safe place. In the event you have a concern or problem with your implant, you can use this card to describe the implant to your health care provider or to Allergan.

You should immediately report any problems that you notice with your implants to your plastic surgeon. If you believe that you have experienced a serious problem(s) related to your breast implants, you should have your health professional report the problem(s) to the Food and Drug Administration (FDA) and/or to Allergan. You may also report any serious problem (sometimes referred to as an "adverse event") directly through the FDA's MedWatch voluntary reporting system. An adverse event is considered serious and should be reported when it results in a hospitalization, disability, congenital problem with your child, or other medical or surgical intervention. The information reported to MedWatch is entered into databases to be used to follow safety trends (patterns) of a device and to determine whether further follow-up of any potential safety issues related to the device is needed.

To report, use MedWatch form 3500, which may be obtained through FDA's website at <https://www.fda.gov/Safety/MedWatch/>. You may also call 1.888.INFO.FDA (1.888.463.6332), 10am-4pm Eastern Time, Monday through Friday, to receive an additional FDA MedWatch Package. Keep a copy of the MedWatch form completed by your surgeon for your records.

6.2 What Is Device Tracking?

Silicone gel-filled breast implants are subject to Device Tracking by Federal regulation. This means that your physician will be required to submit to Allergan the serial number of the implant(s) you receive, the date of surgery, information relating to the physician's practice and information on the patient receiving the implant(s). Your surgeon will write this information on the Device Tracking Form supplied by Allergan with each silicone-filled breast implant. Your surgeon will return the top portion of the form to Allergan following surgery. The second page of the form will be provided to you following surgery. You have the right to remove your personal information from Allergan's Device Tracking program. If you choose NOT to participate in Device Tracking, please check the appropriate box on the Device Tracking form and return to Allergan. You also have the right to have your personal information withheld from

disclosure to third parties who may request information from Allergan, such as the FDA. If you choose to participate in the Device Tracking program but do NOT want your personal information to be released to third parties, please also check the appropriate box.

Allergan strongly recommends that all patients receiving **NATRELLE**[®] Silicone-Filled Breast Implants or **NATRELLE INSPIRA**[®] Breast Implants participate in Allergan's Device Tracking program. This will help ensure that Allergan has a record of each patient's contact information so that all patients can be contacted in the case of a recall or other problems with your implants.

Assessment of Information Effectiveness

The "Required Information" section of the Device Tracking Form also has a question designed to assess the effectiveness of the Breast Augmentation with **NATRELLE**[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®] Breast Implants patient brochure provided prior to your surgery. This question asks you to verify that you received and had adequate time to review this patient labeling information. Please check either yes or no. When the Required Information section is complete, return the entire page to Allergan by mail, using the information provided on the form.

Please inform Allergan whenever your contact information changes by calling 1.800.972.9378 or e-mailing AbbVie_Device_Tracking@AbbVie.com.

6.3 What Is the *ConfidencePlus*[®] Limited Warranty?

The *ConfidencePlus*[®] Limited Warranty provides lifetime replacement and limited financial reimbursement in the event of shell leakage or breakage resulting in implant rupture, subject to certain conditions as fully discussed in the *ConfidencePlus*[®] literature. Our *ConfidencePlus*[®] Premier Limited Warranty program applies automatically to every Allergan **NATRELLE**[®] Silicone-Filled Breast Implant or **NATRELLE INSPIRA**[®] Breast Implant recipient subject to the conditions discussed in the *ConfidencePlus*[®] literature. For more information, please visit www.cppwarranty.com or contact Allergan's Product Surveillance Department at 1.800.624.4261.

6.4 How Can I Receive More Information?

You can request a copy of the physician labeling (Directions for Use; **NATRELLE**[®] Silicone-Filled Breast Implants and **NATRELLE INSPIRA**[®] Breast Implants). It can also be found on www.allerganlabeling.com. The DFU has many undefined medical and technical terms because it contains information written for the surgeon and medical staff.

For more detailed information on the preclinical and clinical studies conducted by Allergan, you are referred to the Summary of Safety and Effectiveness Data (SSED) for this product which may be accessed at https://www.accessdata.fda.gov/cdrh_docs/pdf2/P020056B.pdf.

If, after reading this information, you have additional questions about breast implants or breast implant surgery, there are a number of resources available to you.

6.5 What is the National Breast Implant Registry?

The Plastic Surgery Foundation has developed the National Breast Implant Registry (NBIR) in collaboration with the FDA, patients and breast implant manufacturers to strengthen the post-market surveillance infrastructure for current and future breast implant devices in the United States. The NBIR, first launched in 2018, is a quality improvement initiative and safety surveillance registry that collects clinical, procedural and outcomes data at the time of operation and any subsequent reoperations for all US patients receiving breast implants. NBIR allows surgeons to register implants with the manufacturers for the purpose of device tracking while also submitting data to the registry.

TOLL-FREE NUMBER

If you are a patient or a prospective patient and wish to speak to an Allergan Breast Implant Support Specialist to inquire about breast implants, discuss any concerns, or request a copy of the patient labeling or package insert (Directions for Use), call toll free at 1.800.678.1605 (7 am to 5 pm Pacific Time).

ADDITIONAL RESOURCES

Allergan

1.800.624.4261

www.natrelle.com

www.allergan.com

Institute of Medicine Report on the Safety of Silicone Implants

www.nap.edu/catalog/9618.html

Food and Drug Administration

1.888.INFO.FDA or 1.888.463.6332

www.fda.gov/breastimplants

FOR FURTHER READING AND INFORMATION

Overall Safety Assessment

1. Bondurant, S., Ernster, V., and Herdman, R., Eds. 2000. Safety of silicone breast implants. Committee on the Safety of Silicone Breast Implants, Division of Health Promotion and Disease Prevention, Institute of Medicine. Washington, D.C.: *National Academy Press*.
2. McLaughlin, J., et al. 2007. The safety of silicone gel-filled breast implants: A review of the epidemiologic evidence. *Ann. Plast. Surg.* 59(5):569-80.

Benefits of Breast Augmentation

3. Gladfelter, J. and Murphy, D. 2008. Breast augmentation motivations and satisfaction. *Plast Surg Nurs* 28(4):170-174.
4. Independent Review Group. 1998. Silicone Gel Breast Implants: The report of the Independent Review Group. Silicone gel breast implants Independent Review Group, 9th Floor, Hannibal House, Elephant and Castle, London SE1 6TQ.
5. Young, V.L., 1994. The efficacy of breast augmentation: breast size increase, patient satisfaction, and psychological effects. *Plast Reconstr Surg* 94(7): 958-69.

Implant Rupture

6. Heden P., et al. 2006. Prevalence of rupture in Inamed silicone breast implants. *Plast. Reconstr.Surg.* 118:303-8.
7. Hölmich, L.R., et al. 2005. The diagnosis of silicone breast implant rupture. Clinical findings compared to findings at magnetic resonance imaging. *Ann. Plast. Surg.* 54(6):583-9.
8. Hölmich, L.R., et al. 2005. The diagnosis of breast implant rupture: MRI findings compared to findings at explantation. 2005. *Eur. J. Radiol.* 53(2):213-25.
9. Hölmich, L.R., et al. 2004. Untreated silicone breast implant rupture. *Plast. Reconstr. Surg.* 114(1):204-14.
10. Hölmich, L.R., et al. 2001. Prevalence of silicone breast implant rupture among Danish women. *Plast. Reconstr. Surg.* 108(4):848-58.

Capsular Contracture

11. Baker, J.L. Augmentation mammoplasty. In: Owsley, J.Q. and Peterson, R., Eds. *Symposium on aesthetic surgery of the breast*. St. Louis, MO: Mosby, 1978:256-263.
12. Henriksen, T.F., et al. 2005. Surgical intervention and capsular contracture after breast augmentation: A prospective study of risk factors. *Ann. Plast. Surg.* 54(4):343-51.
13. Kulmala, I., et al. 2004. Local complications after cosmetic breast implant surgery in Finland. *Ann. Plast. Surg.* 53(5):413-9.

14. Seify, H., et al. 2005. Preliminary (3 years) experience with smooth wall silicone gel implants for primary breast augmentation. *Ann. Plast. Surg.* 54(3):231-5.

Pain

15. Hvlisom, G.B., et al. 2009. Local complications after Cosmetic Breast Augmentation: Results from the Danish Registry for Plastic Surgery of the Breast. *Plast. Reconstr. Surg.* 124(3):919-925.

Connective Tissue Disease (CTD)

16. Balk EM, Earley A, Avendano EA, Raman G. Long-term health outcomes in women with silicone gel breast implants: a systematic review. *Ann Intern Med.* 2016;164(3):164-175.
17. Blackburn, W.D., Jr. and Everson, M.P. 1997. Silicone-associated rheumatic disease: an unsupported myth. *Plast Reconstr Surg.* 99:1362-1367.
18. Brinton, L.A., et al. 2004. Risk of connective tissue disorders among breast implant patients. *Am. J. Epidemiol.* 160(7):619-27.
19. Brown, S.L., Duggirala, H.J., and Pennello, G. 2002. An association of silicone-gel breast implant rupture and fibromyalgia. *Curr Rheumatol Rep.* 4:293-298.
20. Brown, S.L., et al. 2001. Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women. *J. Rheumatol.* 28(5):996-1003.
21. Fryzek, J.P. et al. 2007. A nationwide study of connective tissue disease and other rheumatic conditions among Danish women with long-term cosmetic breast implantation. *Ann Epidemiol.* 17:374-379.
22. Greenland, S. and Finkle, W.D. 2000. A retrospective cohort study of implanted medical devices and selected chronic diseases in Medicare claims data. *Ann Epidemiol.* 10:205-213.
23. Hochberg, M.C. and Perlmutter, D.L. 1996. The association of augmentation mammoplasty with connective tissue disease, including systematic sclerosis (scleroderma): a meta-analysis. *Curr Top Microbiol Immunol.* 210:411-417.
24. Hölmich, L.R., et al. 2003. Self-reported diseases and symptoms by rupture status among unselected Danish women with cosmetic silicone breast implants. *Plast. Reconstr. Surg.* 111(2):723-32.
25. Janowsky, E.C., et al. 2000. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. *N. Engl. J. Med.* 342(11):781-90.
26. Kjølner, K. et al. 2001. Connective tissue disease and other rheumatic conditions following cosmetic breast implantation in Denmark. *Arch Intern Med.* 161:973-979.

27. Lamm, S.H. 1998. Silicone breast implants, breast cancer and specific connective tissue diseases: A systematic review of the data in the epidemiological literature. *Int J Toxicol.* 17:457-497.
28. Lee IM, Cook NR, Shadick NA, Pereira E, Buring JE. Prospective cohort study of breast implants and the risk of connective-tissue diseases. *Int J Epidemiol.* 2011;40(1):230-238.
29. Lewin, S.L. and Miller, T.A. 1997. A review of epidemiologic studies analyzing the relationship between breast implants and connective tissue diseases. *Plast Reconstr Surg.* 100:1309-1313.
30. Lipworth, L., et al. 2004. Silicone breast implants and connective tissue disease: An updated review of the epidemiologic evidence. *Ann. Plast. Surg.* 52(6):598-601.
31. Silverman, B.G. et al. 1996. Reported complications of silicone gel breast implants: an epidemiologic review. *Ann Intern Med.* 124:744-756.
32. Tugwell, P., et al. 2001. Do silicone breast implants cause rheumatologic disorders? A systematic review for a court-appointed national science panel. *Arthritis Rheum.* 44(11):2477-84.
33. Vermeulen, R.C. and Scholte, H.R. 2003. Rupture of silicone gel breast implants and symptoms of pain and fatigue. *J Rheumatol.* 30:2263-2267.
34. Weisman, M.H., et al. 1988. Connective-tissue disease following breast augmentation: A preliminary test of the human adjuvant tissue hypothesis. *Plast. Reconstr. Surg.* 82(4):626-30.
35. Williams, H.J., et al. 1997. Breast implants in patients with differentiated and undifferentiated connective tissue disease. *Arthritis Rheum.* 40(3):437-40.
36. Wolfe, F. and Anderson, J. 1999. Silicone filled breast implants and the risk of fibromyalgia and rheumatoid arthritis. *J. Rheumatol.* 26(9):2025-8.
37. Wong, O. 1996. A critical assessment of the relationship between silicone breast implants and connective tissue diseases. *Regul Toxicol Pharmacol.* 23:74-85.

CTD Signs and Symptoms

38. Berner, I., et al. 2002. Comparative examination of complaints of patients with breast-cancer with and without silicone implants. *Eur. J Obstet. Gynecol. Reprod. Biol.* 102(1):61-6.
39. Breiting, V.B., et al. 2004. Long-term health status of Danish women with silicone breast implants. *Plast. Reconstr. Surg.* 114(1):217-26.
40. Fryzek, J.P., et al. 2001. Self-reported symptoms among women after cosmetic breast implant and breast reduction surgery. *Plast. Reconstr. Surg.* 107(1):206-13.
41. Kjølner, K., et al. 2004. Self-reported musculoskeletal symptoms among Danish women with cosmetic breast implants. *Ann. Plast. Surg.* 52(1):1-7.

Cancer

42. Brinton, L.A., et al. 2000. Breast cancer following augmentation mammoplasty (United States). *Cancer Causes Control*. 11(9):819-27.
43. Brinton, L.A., et al. 2001. Cancer risk at sites other than the breast following augmentation mammoplasty. *Ann. Epidemiol.* 11(4):248-56.
44. Brisson, J. et al. 2006. Cancer incidence in a cohort of Ontario and Quebec women having bilateral breast augmentation. *Int J Cancer*. 118:2854-2862.
45. Bryant, H., and Brasher, P. 1995. Breast implants and breast cancer—reanalysis of a linkage study. *N. Engl. J. Med.* 332(23):1535-9.
46. Cook, L.S. 1997. Characteristics of women with and without breast augmentation. *JAMA*. 277(20):1612-7.
47. Deapen, D.M., et al. 1997. Are breast implants anticarcinogenic? A 14-year follow-up of the Los Angeles Study. *Plast. Reconstr. Surg.* 99(5):1346-53.
48. Deapen, D., et al. 2000. Breast cancer stage at diagnosis and survival among patients with prior breast implants. *Plast. Reconstr. Surg.* 105(2):535-40.
49. Deapen, D.M., Hirsch, E.M. and Brody, G.S. 2007. Cancer risk among Los Angeles women with cosmetic breast implants. *Plast Reconstr Surg*. 119:1987-1992.
50. de Boer M, van Leeuw FE, Hauptmann M, et al Breast implants and the risk of anaplastic large-cell lymphoma in the breast. *JAMA oncology* 2018;4(3):335-341
51. De Jong, D., et al. 2008. Anaplastic large-cell lymphoma in women with breast implants. *JAMA*. 300(17): 2030-5.
52. Doren E, Miranda R, Selber J, Garvey P, Liu J, Medeiros J, Butler C, Clemens M. U.S. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Plastic and Reconstructive Surgery*. 2017 May; Vol. 139, No. 5, pp. 1042-1050.
53. Friis, S. et al. 2006. Cancer risk among Danish women with cosmetic breast implants. *Int J Cancer*. 118:998-1003.
54. Fryzek, J.P., et al. 2000. Characteristics of women with cosmetic breast augmentation surgery compared with breast reduction surgery patients and women in the general population of Sweden. *Ann. Plast. Surg.* 45(4):349-56.
55. Herdman, R.C., et al. 2001. Silicone breast implants and cancer. *Cancer Invest.* 19(8):821-32.
56. Jakubietz, M.G., et al. 2004. Breast augmentation: Cancer concerns and mammography—A literature review. *Plast. Reconstr. Surg.* 113(7):117e-22e.

57. Kjølner K., et al. 2003. Characteristics of women with cosmetic breast implants compared with women with other types of cosmetic surgery and population-based controls in Denmark. *Ann. Plast. Surg.* 50(1):6-12.
58. Lipworth, L., et al. 2009. Cancer among Scandinavian women with cosmetic breast implants: A pooled long-term follow-up study. *Int. J. Cancer.* 124(2):490-3.
59. Lipworth, L., et al. 2009. Breast implants and lymphoma risk: A review of the epidemiologic evidence through 2008. *Plast. Reconstr. Surg.* 123(3):790-3.
60. Loch-Wilkinson A, Beath K, Knight R J W, Wessels W L F, Magnusson M, Papadopoulos T, Connell T, Lofts J, Locke M, Hopper I, Cooter R, Vickery K, Joshi P A, Prince H M, Deva A. Breast implant associated Anaplastic Large Cell Lymphoma in Australia and New Zealand - high surface area textured implants are associated with increased risk. *Plastic and reconstructive surgery.* 2017 May 5.
61. McLaughlin, J.K. and Lipworth, L. 2004. Brain cancer and cosmetic breast implants: A review of the epidemiological evidence. *Ann. Plast. Surg.* 52(2):15-7.
62. McLaughlin, J.K. et al. 2006. Long-term cancer risk among Swedish women with cosmetic breast implants: an update of a nationwide study. *J Natl Cancer Inst.* 98:557-560.
63. Mellemkjaer, L. et al. 2000. Cancer occurrence after cosmetic breast implantation in Denmark. *Int J Cancer.* 88:301-306.
64. Miglioretti, D.L., et al. 2004. Effect of breast augmentation on the accuracy of mammography and cancer characteristics. *JAMA.* 291(4):442-50.
65. Pukkala, E., et al. 2002. Incidence of breast and other cancers among Finnish women with cosmetic breast implants, 1970-1999. *J. Long Term Eff. Med. Implants.* 12(4):271-9.

Neurological Disease, Signs, and Symptoms

66. Englert, H. et al. 2001. Women's health after plastic surgery. *Intern Med J.* 31:77-89.
67. Winther, J.F. et al. 2001. Neurological disease among women with silicone breast implants in Denmark. *Acta Neurol Scand.* 103:93-96.

Suicide

68. Brinton, L.A., et al. 2001. Mortality among augmentation mammoplasty patients. *Epidemiol.* 12(3):321-6.
69. Jacobsen, P.H., et al. 2004. Mortality and suicide among Danish women with cosmetic breast implants. *Arch. Int. Med.* 164(22):2450-5.
70. Klesmer, J. 2003. Mortality in Swedish women with cosmetic breast implants: body dysmorphic disorder should be considered. *BMJ.* 326:1266-1267.

71. Koot, V., et al. 2003. Total and cause specific mortality among Swedish women with cosmetic breast implants: Prospective study. *BMJ*. 326(7388):527-8.
72. Le, G.M. et al. 2005. Breast Implants following mastectomy in women with early-stage breast cancer: prevalence and impact on survival. *Breast Cancer Res.* 7:R184-193.
73. Lipworth, L. et al. 2007. Excess mortality from suicide and other external causes of death among women with cosmetic breast implants. *Ann Plast Surg.* 59:119-123; discussion 115-124.
74. McLaughlin, J.K., Lipworth, L., and Tarone, R.E. 2003. Suicide among women with cosmetic breast implants: a review of the epidemiologic evidence. *J Long Term Eff Med Implants.* 13:445-450.
75. Pukkala, E., et al. 2003. Causes of death among Finnish women with cosmetic breast implants, 1971-2001. *Ann. Plast. Surg.* 51(4):339-42.
76. Villeneuve, P.J. et al. 2006. Mortality among Canadian women with cosmetic breast implants. *Am J Epidemiol.* 164:334-341.

Effects on Breastfeeding/Children

77. Brown, S.L., Todd, J.F., Cope, J.U. and Sachs, H.C. 2006. Breast implant surveillance reports to the U.S. Food and Drug Administration: maternal-child health problems. *J Long Term Eff Med Implants.* 16:281-290.
78. Hemminki, E., et al. 2004. Births and perinatal health of infants among women who have had silicone breast implantation in Finland, 1967-2000. *Acta Obstet. Gynecol. Scand.* 83(12):1135-40.
79. Kjøller, K., et al. 2002. Health outcomes in offspring of Danish mothers with cosmetic breast implants. *Ann. Plast. Surg.* 48(3):238-45.
80. Signorello, L.B., et al. 2001. Offspring health risk after cosmetic breast implantation in Sweden. *Ann. Plast. Surg.* 46(3):279-86.

Silicone Gel Migration

81. Katzin, W.E., et al. 2005. Pathology of lymph nodes from patients with breast implants: A histologic and spectroscopic evaluation. *Am. J. Surg. Pathol.* 29(4):506-11.

Gel Bleed

82. Chandra, G., et al. 1987. A convenient and novel route to bis(alkyne)platinum(0) and other platinum(0) complexes from Speier's hydrosilylation catalyst. *Organometallics.* 6:191-2.
83. Flassbeck, D.B., et al. 2003. Determination of siloxanes, silicon, and platinum in tissues of women with silicone gel-filled implants. *Anal. Bioanal. Chem.* 375(3):356-62 (for example, data from Patients B & C).

84. Lappert, M.F. and Scott, F.P.A. 1995. The reaction pathway from Speier's to Karstedt's hydrosilylation catalyst. *J. Organomet. Chem.* 492(2):C11-C13.
85. Lewis, L.N., et al. 1995. Mechanism of formation of platinum(0) complexes containing silicon-vinyl ligands. *Organometallics.* 14:2202-13.
86. Lugowski, S.J., et al. 2000. Analysis of silicon in human tissues with special reference to silicone breast implants. *J. Trace Elem. Med. Biol.* 14(1):31-42.
87. Stein, J., et al. 1999. In situ determination of the active catalyst in hydrosilylation reactions using highly reactive Pt(0) catalyst precursors. *J. Am. Chem. Soc.* 121(15):3693-703.

INDEX

Alternatives to silicone breast implants.....	35
Anaplastic Large Cell Lymphoma (ALCL)	27
Anesthesia	42
Benefits	19
Biopsy.....	26
Breast measurement	46
Breast reconstruction	17
Breastfeeding	26, 34, 55
Cancer.....	27, 32, 55
Capsule.....	24
Complications.....	11, 43
ConfidencePlus®	57
Connective tissue disease (CTD).....	31
Contraindications	17
Core Study.....	44
CTD.....	54
CTD signs and symptoms.....	31, 54
Device identification card.....	56
Device tracking	56
Effects on children	34
Food and Drug Administration (FDA).....	56
Gel diffusion.....	37
Implant palpability	42
Implant placement	40
Implant Shape and Size	38
Inframammary.....	41
Lactation complications.....	55
Mammography	33, 44
Mastopexy	41
MedWatch	56
Neurological disease	33
Patient satisfaction	46
Periareolar	41
Postoperative care	42
Precautions.....	18
Quality of life assessments....	47
Reproduction complications ..	55
Rupture from literature	31
Screening	43
Silent Rupture	43
Suicide.....	34, 55
Summary of Safety and Effectiveness Data (SSED).....	58
Surgeon.....	35
Surgical setting	42
Symptomatic Rupture	44
Toxic shock syndrome.....	25
Transaxillary	41
Umbilical	41
Warnings	18

ACKNOWLEDGEMENT OF INFORMED DECISION AND PATIENT DECISION CHECKLIST

I understand that the patient labeling provided by Allergan is intended to provide information regarding the benefits and risks of silicone gel breast implants. I understand that some of this information is about breast implants in general and some is specific to Allergan's breast implants. I understand that choosing to have augmentation breast surgery with implants involves both benefits and risks. I also understand that scientists and doctors have not been able to identify or quantify all of the risks of breast augmentation with implants and that, over time, additional information may become available.

I have had adequate time to review and understand the information presented in the printed patient brochure, *Important Factors Breast Augmentation and Reconstruction Patients Should Consider*, and the electronic patient labeling, *Breast Augmentation with NATRELLE® Silicone-Filled Breast Implants and NATRELLE INSPIRA® Breast Implants*. My concerns and questions have been addressed by my doctor. I have considered alternatives to augmentation surgery, including use of external prostheses or surgery with saline-filled breast implants.

PATIENT DECISION CHECKLIST

To the patient considering breast implants filled with saline or silicone gel intended for breast augmentation or breast reconstruction:

The review and understanding of this document is a critical step in making the decision whether you should choose breast implant surgery. You should learn about breast implants and then carefully consider the benefits and risks associated with breast implants and breast implant surgery before you make that decision. This form lists important risks, including those known or reported to be associated with the use of the device based on information from clinical trials, scientific literature, and reports from patients who have undergone device placement.

This Patient Decision Checklist is intended to supplement the additional patient information documents that should be provided to you by your physician. You should receive patient information documents that include important information about your specific breast implant, as well as a boxed warning and Patient Decision Checklist. After reviewing the information in the patient information documents for the specific implant that will be used, please read and discuss the items in this checklist carefully in consultation with your physician. You should place your initials in the location provided next to each item to indicate that you have read and understood the item. Your full signature at the end of this document confirms that you have read the materials and that your physician has answered all questions to your satisfaction.

Considerations for a Candidate for Successful Breast Implantation

I understand that I am not a candidate for breast implants if any of the following situations applies to me:

- I have an active infection anywhere in my body;
- I have an existing cancer or pre-cancer of my breast tissue that has not been adequately treated; or
- I am pregnant or nursing.

I understand that if I have any of the following conditions, I may be at a higher risk for a poor surgical outcome:

- Medical condition that affects my body's ability to heal (e.g., diabetes, connective tissue disorder);
- Active smoker or a former smoker;
- Currently taking drugs that weaken the body's natural resistance to disease, such as steroids and chemotherapy drugs (e.g., prednisone, tacrolimus, sirolimus, mycophenolate, azathioprine, cyclosporine, methotrexate, chlorambucil, leflunomide, or cyclophosphamide);
- History of chemotherapy or planned chemotherapy following breast implant placement;
- History of radiation therapy or planned radiation following breast implant placement;
- Conditions that interfere with wound healing or blood clotting (e.g., hemophilia, von Willebrand disease, factor V Leiden, hyperhomocysteinemia, protein C deficiency, antithrombin III deficiency, or systemic lupus erythematosus); or
- Reduced blood supply to the breast tissue.

I understand the following conditions have not been adequately studied to determine whether the conditions put me at higher risk:

- Autoimmune disease (e.g., Hashimoto's, Lupus, Rheumatoid Arthritis) or family history of autoimmune disease (breast implant premarket clinical studies have not evaluated the safety of breast implants in patients with autoimmune disease);
- Clinical diagnosis of depression or other mental health disorder (including body dysmorphic disorder or eating disorder); or
- Have other products permanently implanted in the breast.

Patient Initials: _____

Risks of Breast Implant Surgery

I understand that there are risks of undergoing breast implant surgery. I understand that risks of undergoing breast implant surgery may include:

- breast pain (reported in up to 11.7% of patients¹),
- skin or nipple areola sensitivity changes or loss (nipple complications reported in up to 6.3% of patients¹ and breast/skin sensation changes reported in up to 2.2% of patients¹),
- asymmetry (reported in up to 23.2% of patients¹),
- impact of aging or weight change on size and shape of breast (ptosis reported in up to 4.9% of patients¹),
- infection requiring possible removal of implant (reported in up to 3.2% of patients¹),
- swelling (reported in up to 9.2% of patients¹),
- scarring (hypertrophic scarring reported in up to 6.6% of patients¹),
- fluid collections (seroma)(reported in up to 6.7% of patients¹),
- hematoma (reported in up to 2.1% of patients¹),
- tissue death of breast skin or nipple (tissue/skin necrosis reported in up to 2.3% of patients¹),
- inability to breast feed (lactation complications reported in up to 30% of patients¹),
- complications of anesthesia (may occur but specific rates are not publicly available in the Allergan Core Study),
- bleeding (may occur but specific rates are not publicly available in the Allergan Core Study),
- chronic pain (may occur but specific rates are not publicly available in the Allergan Core Study),
- damage to surrounding tissue, such as muscle, nerves, and blood vessels (may occur but specific rates are not publicly available in the Allergan Core Study), and
- impact on imaging of breast tissue (may occur but specific rates are not publicly available in the Allergan Core Study).

My physician has discussed these risks and has provided me with the patient information documents (including the boxed warning) with information on the types of risks that are possible and expected rates of occurrence.

My physician has discussed the potential use of other implanted products during my breast implant surgery. My physician has also discussed the risks and benefits of using these implanted products and their planned surgical approach.

Patient Initials: _____

¹ Based on the largest complication rate reported in the Core Clinical Study through 10-years of follow-up. See Section 5.0 of either the Breast Augmentation or Reconstruction with **NATRELLE®** Silicone-Filled Breast Implants and **NATRELLE INSPIRA®** Breast Implants with Smooth Surface Patient Brochures.

Risk of Cancer - Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

I understand that breast implants are associated with the development of a type of cancer of the immune system called Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Information regarding the number of medical device reports of BIA-ALCL can be found on FDA's website.²

As of July 2019, literature reports various estimates for the incidence of BIA-ALCL. These estimated incidence rates range from a high of 1 per 3,817 patients to 1 in 30,000. (Clemens et al, 2017, Loch-Wilkinson 2017 et al, De Boer et al, 2018).

I have received information regarding the overall incidence rates of BIA-ALCL and the rates as they pertain to my specific breast implant.

I understand that this cancer has been reported more frequently for textured breast implants, but patients with smooth surfaced implants have also been diagnosed.

I understand that patients with breast implants have a risk of developing BIA-ALCL within the scar tissue and fluid surrounding the breast implant.

I understand that BIA-ALCL typically takes several years to develop after implantation, but cases have been reported as early as within one year. Typical symptoms to be aware of may include: breast tightness, pain, lumps, or swelling of the breast months or years after I receive my implants.

I understand that treatment for BIA-ALCL involves an operation to remove the implants and the surrounding scar tissue capsule. Based on the stage of the cancer at diagnosis, some patients have required chemotherapy or radiation. While BIA-ALCL typically responds well to therapy, some patients have died from BIA-ALCL. Diagnosis and treatment may be at my own expense and is not always covered by insurance.

Patient Initials: _____

² See "Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma," available at <https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma>.

Systemic Symptoms

I understand that some patients who have received breast implants have reported a variety of systemic symptoms including joint pain, fatigue, rash, memory loss, and "brain fog" that some patients have called breast implant illness. While the causes of these symptoms are unclear, some patients have reported relief of these symptoms with removal of their implants and surrounding scar capsule; however, not all patients may experience improvement in their symptoms. Researchers are working to better understand the possible link between breast implants and these symptoms.

I also understand that some patients with breast implants have reported health problems in their children after birth or breastfeeding. A causal link has not been established between breast implants and these reported health problems in children and more research is needed. I understand that breast implants and breast surgery may interfere with my ability to successfully breastfeed.

Patient Initials: _____

Breast-Implant Specific Risks

I understand that a breast implant is NOT a lifetime device and the longer I have my implants, the more likely I am to experience a complication and the more likely I am to need a reoperation requiring the replacement or removal of my breast implant. As many as 32.4% of women who received breast implants for augmentation had their implants removed within 10 years, but my implants may last for a shorter or longer period of time. (The percentage reported is from the 10-year Core Clinical Study for **NATRELLE**[®] Silicone gel-filled breast implants. The rate specified represents the largest reported cumulative 10-year rate across all groups of augmentation patients in the study (both primary and revision)).

I understand that my breast implant may rupture or leak at any time, and that the longer I have my implants, the more likely I am to experience a complication such as rupture. I understand that gel bleed (small quantities of gel diffusing from the implant shell) of silicone gel-filled implants may occur. I understand that if I have a saline-filled implant, my breast may deflate in appearance if there is a rupture or leakage of the saline.

I understand that if I have a silicone gel-filled breast implant, I or the physician may not be able to tell on physical exam whether my implant has ruptured or is leaking silicone gel. Because rupture or leakage of silicone gel-filled breast implants is difficult to detect, I understand that periodic imaging evaluation is recommended for screening of silicone gel-filled breast implant rupture. It is recommended that I have periodic imaging of my silicone gel-filled breast implants to screen for implant rupture regardless of whether my implants are for cosmetic augmentation or reconstruction. These recommendations do not replace other additional imaging that may be required depending on my medical history or circumstances (i.e., screening mammography for breast cancer).

Even if I have no symptoms, I should have regular imaging evaluations as described in the "Recommended Follow-Up" section below. These imaging evaluations may not detect all ruptures or leaks, and the expense may not be covered by my medical insurance.

I understand that there are rare case reports of silicone migrating from breast implants into tissues (e.g., chest wall, lymph nodes under the arm) and organs (e.g., liver, lungs). It may not be possible to remove migrated silicone.

I understand that all breast implants can affect mammography and breast exams, which could potentially delay the diagnosis of breast cancer. Mammography can also cause the breast implant to rupture or leak. I should tell the mammography technician if I have breast implants.

I understand that the long-term risks of breast implants may include:

- painful or tightening of scar tissue (capsule) around my implant (capsular contracture III/IV) (reported in up to 28.7% of patients¹),
- rupture or leaking of the implant (reported in up to 35.4% of patients¹),
- wrinkling of the implant (wrinkling/rippling reported in up to 10.2% of patients¹),
- visibility of the implant edges (implant palpability/visibility reported in up to 6.7% of patients¹),
- shifting of the implant (implant malposition reported in up to 13.3% of patients¹), or
- reoperation (reported in up to 71.5% of patients¹).

I understand that I will receive a Device Identification Card after my surgery that has information on each of my specific implants. I understand that it is important for me to keep each card in case, at some time in the future, I or my physician need to know what kind of implant I received many years later.

I understand that breast implant manufacturing requires the use of chemicals and heavy metals. I understand that most of these chemicals stay inside the shell of the implant. Small quantities may diffuse (gel bleed) through the implant shell of silicone gel-filled implants, even if the implant is intact and not ruptured or leaking.

A list of the components, chemicals, and heavy metals is available in the section entitled, "**NATRELLE® Silicone-Filled/Saline-Filled Breast Implant Device Materials**" of the patient information document.

Patient Initials: _____

Recommended Follow-up

Even if I have no symptoms, I should have my first ultrasound or MRI at 5-6 years after my initial implant surgery and then every 2-3 years thereafter. If I have symptoms or uncertain ultrasound results for breast implant rupture, an MRI is recommended.

I understand that for as long as I have my breast implant(s), I will need routine and regular follow-up with my physician, for examination of my breast implant(s) as well as to discuss any updates regarding breast implant issues.

National Breast Implant Registry (NBIR): I understand and have discussed with my physician that there is a National Breast Implant Registry where information regarding my health and breast implant information can be entered. The NBIR may help understand the long-term safety and performance of breast implants.

Patient Registry and Outcomes For breast Implants and anaplastic large cell Lymphoma (ALCL) etiology and Epidemiology (PROFILE): I understand and have discussed with my physician that there is a registry (PROFILE) where information is collected to better understand BIA-ALCL in patients with breast implants.

Patient Initials: _____

Questions for My Physician

I have had the opportunity to ask my physician questions about his or her experience, medical degree, specialty of training, and credentials. I understand that breast implants have associated procedural risks and should only be used by physicians who are appropriately trained.

Patient Initials: _____

Options Following Mastectomy

I understand that breast reconstruction is an elective procedure, which I can choose to do or not.

I understand that I may choose not to have breast reconstruction (“going flat”) and may choose to use an external prosthesis in my bra to look like I have a breast when wearing clothes.

I understand the surgical options for breast reconstruction, including the use of a breast implant and the use of my own tissue (“autologous reconstruction”).

I understand that if my breast implants are ever removed, I may be left with dimpling, chest wall concavity, puckering, or sagging of my breasts or skin.

I understand that more surgeries may be necessary in the future due to complications or to remove or replace the breast implants.

I have discussed all of the options for breast reconstruction with my surgeon, including whether I am a candidate and the benefits and risks of each, and I believe that breast reconstruction with a breast implant is the best option for me.

Patient Initials: _____

Breast Augmentation Options

I understand that breast augmentation is an elective procedure to increase the size of my breasts.

I understand that breast augmentation may result in permanent changes to my breast tissue and if my implants are ever removed, I may be left with an unsatisfactory appearance, changes to the size and shape of my breasts, including but not limited to dimpling, chest-wall concavity, puckering, sagging, or different incision size or location.

If I am an augmentation patient, any additional surgeries or medical procedures will likely be at my own expense.

Patient Initials: _____

CONFIRMATION OF DISCUSSION OF RISKS

Patient: I acknowledge that I have received and read the patient information documents for the specific implant that will be used during my surgery and that I have had time to discuss the information in it and on this document with my physician. I have had the opportunity to ask questions and understand the benefits and risks of breast implants for me, given my specific health conditions. I have considered alternatives to breast implants, including reconstruction without breast implants, no reconstruction/augmentation, and their respective benefits and risks.

Patient Signature and Date

Physician: I acknowledge that I have discussed the benefits and risks of breast implants as described elsewhere in the patient information documents and in this checklist. I have also explained the benefits and risks of the alternatives. I have encouraged the patient to ask questions, and I have addressed all questions.

Physician Signature and Date

Natrelle®

Allergan Sales, LLC
2525 Dupont Drive
Irvine, CA 92612
1.800.624.4261

www.allergan.com

